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ABSTRACT
ENGINEERING THE MOSQUITO SYMBIONT PANTOEA AGGLOMERANS
TO SECRETE PLASMODIUM INHIBITORY PROTEINS

By
Dawn C. Bisi

August 2009

Dissertation Supervised by Dr. David J. Lampe
The disease malaria originates from the transmission of the parasite Plasmodium
to humans by female anopheline mosquitoes. Estimates put the number of deaths at 1-3
million people annually and this number will increase without the establishment of new
control strategies. There is currently no vaccine and the effectiveness of insecticides and
drugs are thwarted by the gain of resistances for both the insect and parasite. An
alternative genetic engineering approach to combating malaria is presented here. The
bacterial mosquito symbiont Pantoea agglomerans, which resides in the mosquito gut,
was chosen to express anti-Plasmodium effector gene products that are known to inhibit
Plasmodium development. A caveat is finding an appropriate protein secretion signal for
export of the effectors from the cell. A two-pronged approach to finding a secretion
signal involved identifying and testing a native secreted protein signal in
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P. agglomerans, and also testing heterologous secretion signals shown to work
previously in related species. Proteomic analysis of native secreted proteins in spent
growth medium followed by the identification of the corresponding genes revealed the
best native candidate for trials was the secreted protein FliC/Flagellin. Various
constructs involving the fliC 5’ UTR and the fliC ORF were used for secretion of a test
protein (an anti-BSA scFv) in P. agglomerans and found to not be a sufficient secretion
signal. The heterologous PelB (from Erwinia carotovora), and OmpA, TolB, and HlyA
(all from E. coli) signals were also used in secretion trials with the anti-BSA scFv. The
PelB and HlyA signals were shown to secrete the scFv in P. agglomerans, however it
was only active in the case of PelB-induced secretion. In addition, four anti-Plasmodium
effector proteins (SM1, Anti-Pbs21, PLA2, and CEL-III) were available for testing in
constructs containing the heterologous secretion signals. Varying success was observed
with the different combinations of signals and effector genes. The OmpA and TolB
signals were not functional in P. agglomerans. P. agglomerans was able to secrete AntiPbs21-HlyA and PLA2 H67N-HlyA fusions and these strains are now available for
testing inside malaria-infected anophelines for the inhibition of Plasmodium
development.
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CHAPTER 1
INTRODUCTION
1.1 Malaria: The Disease and Its Insect Vector
Malaria is a mosquito-vectored disease caused by protozoan parasites of the genus
Plasmodium. It is a very serious and often fatal disease and is a major worldwide health
concern. Around 41% of the human population is at high risk for malaria due to their
residence in the subtropical and tropical areas on Earth. The majority of cases occur in
sub-Saharan Africa, but the disease is also present in parts of South Asia, the Middle
East, and regions of Central and South America. Estimates put the current number of
cases of malaria at approximately 500 million and the number of annual deaths at 1-3
million (BREMAN et al. 2001; SNOW et al. 2005). The Centers for Disease Control and
Prevention estimates that as many as 2.7 million lives are lost to malaria each year (CDC
2006). Most of these deaths occur in African children under the age of five. It cannot be
underestimated that successful efforts to curb the spread of this disease are desperately
needed.
The mosquito vector for malaria, females of the genus Anopheles, thrives in the
hot and humid climate of subtropical and tropical regions. The females bite humans in
order to obtain blood necessary for egg production. If this mosquito is infected with
Plasmodium, it can transmit the parasite to the human while taking a blood meal. Also, a
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naïve mosquito can obtain Plasmodium by feeding on an infected human. This exchange
between human and mosquito is required for a successful Plasmodium life cycle.
Anopheline mosquitoes go through four life cycle stages: egg, larva, pupa, and
adult (or imago). Environmental conditions such as ambient temperature and humidity
will determine the lifespan of an adult mosquito as well as the successful transmission of
malaria. An infected female mosquito must be alive for 9-21 days in order for
Plasmodium to complete the extrinsic phase of its growth cycle. The cycle will be
shorter if ambient temperatures are above 25°C, thus increasing the chance of
transmission to humans who live in the warmer regions on Earth.
There are 400 identified species of Anopheles, and 30-40 of these species have the
capacity to transmit malaria in the wild. An. gambiae and An. funestus are the most
successful malarial vectors in Africa due to their anthropophilic feeding behavior; they
strongly prefer to feed on humans rather than on other mammals. Another species,
An. stephensi, can transmit a malarial parasite called Plasmodium berghei that affects
rodents and is often used as a model research system.
Mosquitoes carrying malaria incur fitness costs from loss of fecundity to
decreased flight distance. As a result, there is significant selective pressure for species
like An. gambiae to carry refractory alleles to Plasmodium. There exists a wide range of
refractoriness across different Anopheles species and the molecular explanation for this
phenomenon is not completely understood. Specific loci that confer resistance to
P. falciparum infection have been identified in W. African mosquito populations (NIARE
et al. 2002). Some An. gambiae strains do not have vectorial capacity because they can
trigger a complement-like immune response against midgut stages of Plasmodium, while
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other strains undergo melanotic encapsulation of the oocyst stage parasites (BLANDIN et
al. 2004; GHOSH et al. 2000). Melanotic encapsulation is an immune response in certain
insects, where foreign objects are encapsulated and targeted for destruction. Even with
these immune defenses against Plasmodium, most anopheline mosquitoes are still
successful malarial vectors, contributing to the rising number of newly infected humans
every year.
1.2 The Parasite Plasmodium causes Malaria
Malaria is caused by parasites within the genus Plasmodium. Depending upon the
species of Plasmodium, malaria can affect many different animals from birds to reptiles
to some mammals. Four species of malarial parasites can infect humans: P. falciparum,
P. vivax, P. ovale, and P. malariae. P. falciparum and P. vivax are responsible for the
most infections throughout the world with the former causing the most severe and
potentially fatal form of the disease. P. ovale or P. malariae infections can result in
dormant liver stage parasites, which can relapse and cause malaria several months to
years after the initial infection. In the case of P. malariae, long-lasting chronic infections
occur, and, if left untreated, can persist asymptomatically throughout the lifetime of the
host.
The Plasmodium parasite has a complicated life cycle involving six distinct
developmental forms: female and male gametes, zygote, ookinete, oocyst, and sporozoite,
as well as fertilization and invasion of several different types of host tissue (GHOSH et al.
2000). A completed life cycle and a successful spread of the parasite require both the
insect and human hosts (Figure 1.1).
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Plasmodium reproduces sexually when inside the gut of the mosquito and must
surpass sequential developmental bottlenecks along the way (Cycle C in Figure 1.1). The
Plasmodium gametocyte (Step 8 in Figure 1.1), first encounters the mosquito midgut
environment and displays proteins on its surface, such as Pbs21 found on P. berghei, that
are used as targets by researchers for blocking development. A small percentage of
gametocytes develop into ookinetes and not much is known about this developmental
transition (Step 10).

Figure 1.1: The life cycle of Plasmodium. Plasmodium needs the human and mosquito hosts for a
successful life cycle. Stages A and B are the nonsexual stages of Plasmodium that occur in the human host.
Upon transmission to a naïve human by an infected mosquito, Plasmodium will first infect liver cells and
eventually invade the bloodstream. When a naïve mosquito takes a blood meal from the infected person,
Plasmodium can be transmitted and will then undergo Stage C, which entails the sexual stages of
development. These occur inside the mosquito gut and eventually the salivary glands. See text for more
details. (Figure from Centers for Disease Control and Prevention website:
http://www.cdc.gov/malaria/biology/life_cycle.htm)
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Within 24 hours, the ookinete makes a difficult journey in traversing both the
peritrophic matrix, a chitin-rich inner lining of the gut, and the midgut epithelium in order
to implant between the midgut epithelium and basal lamina for further differentiation into
oocysts (Step 11). The successful differentiation from ookinete to oocyst can take
anywhere from 10-24 days depending on the Plasmodium species. Oocysts burst to
release thousands of sporozoites that have the ability to invade numerous organs and cell
types, but they will only travel through a second epithelial layer, to the salivary glands
(Step 12).
From the salivary glands, the sporozoites will soon enter the secretory cavity and
will remain there for the life of the mosquito. When the insect takes a blood meal the
sporozoites are transferred to the mammalian host in the insect’s saliva and will migrate
to the liver cells to continue their maturation.
Liver-stage parasites are called schizonts and over the course of a few days they
rapidly divide to form merozoites (Cycle A, Step 2). Merozoites are eventually released
from the parenchymal cells of the liver into the bloodstream where they invade
erythrocytes. Depending on the species, Plasmodium can remain dormant in the liver and
cause a relapse in an infected individual by invading the bloodstream after weeks or even
years. Once present in the blood cells, the parasites reproduce asexually into the
trophozoite stage and go on to produce daughter merozoite-stage parasites that will
invade more red blood cells (Cycle B). It is these blood stage parasites that cause the
clinical manifestations of malaria.
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1.3 The Manifestations of Malaria in Humans
Individuals with malaria can display symptoms that range from nonexistent to
fatal. For this reason, malaria is classified as being either uncomplicated or
complicated/severe. Fortunately, if malaria is diagnosed early and treated properly, it is a
curable disease. With uncomplicated malaria, a patient may present any combination of
flu-like symptoms ranging from nausea and vomiting to body aches and fever. Proper
diagnosis comes only after observing a blood smear under a microscope for the presence
of the parasite.
Complicated malaria involves organ failure and drastic changes in the patient’s
bloodstream and metabolism. This may include hemoglobinuria (hemoglobin in the
urine), pulmonary edema (fluid buildup in the lungs), or cardiovascular collapse and
shock. These extreme cases are seen in individuals with no immunity to malaria,
especially those who reside in areas of low to no malarial transmission. Aggressive
treatment and an urgent response is needed for complicated malaria to attempt to save the
infected individual’s life.
1.4 Past Treatments and Preventive Measures
Prevention and control of malaria thus far has relied primarily on either drug
treatments or insect vector control. Plant-derived anti-malarial drugs such as quinine and
artemisinin have been used for the past several decades to treat malaria. Quinine is
currently only used for treating severe infections with P. falciparum due to its horrible
side effects like temporary deafness, ringing in the ears, and dizziness. Artemisinin can
be administered to patients orally or through intravenous infusion and will target the
parasites present in the bloodstream. Artemisinin acts 10 times faster on Plasmodium
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compared to quinine (WHITTY et al. 2006). By destroying the gametocytes in the
bloodstream, transmission to a feeding mosquito is somewhat reduced. Over time,
however, the effects of artemisinin are reduced because Plasmodium evolves resistance.
In recent years, the drug chloroquine has become ineffective against resistant strains of
P. falciparum, but it is still effective against P. vivax, P. ovale, and P. malariae.
Chloroquine resistance in P. falciparum has been linked to mutations in genes that
encode proteins involved in uptake to the parasite vacuole (LE BRAS and DURAND 2003).
Destruction of mosquito larval breeding grounds and the use of physical barriers
like insecticide-treated bed nets in high-risk locations can help in minimizing mosquito
populations and their interactions with humans. Nets impregnated with pyrethroid
permethrin have an increased effectiveness because this insecticide produces a halo that
extends beyond the surface of the net. However, the nets can be expensive, are not
widely available, and have to be replenished with insecticide twice a year. It is estimated
that less than 5% of nets in use are re-treated sufficiently.
Neither method of drug treatment or vector control is completely successful in
inhibiting malaria transmission. Most importantly, both Plasmodium and Anopheles
species have evolved resistances to many of the drugs and insecticides in use.
Destruction of natural habitats also comes as a price of insecticide use. As a result, there
are a decreasing number of effective and inexpensive means of controlling this disease.
Additional measures must be developed to combat the spread of malaria. There
are some estimates that the number of malaria cases will double in the next 20 years if no
new preventative measures are put into place (BREMAN et al. 2001). To circumvent the
inevitable resistance of the mosquito or parasite to any environmental controls and to
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minimize the destruction of natural habitats, alternative genetic approaches have been
initiated and appear promising.
1.5 Combating Insect-Vectored Diseases with Genetic Approaches
There have been numerous attempts to control malaria by genetically altering the
mosquito in a way that would turn it into an ineffective malarial vector (ALPHEY et al.
2002; MOREIRA et al. 2002a). Using this strategy, the insect is modified to prevent the
parasite from traveling from the gut to the salivary glands or from the insect to the
human, resulting in a reduction of malarial transmission. The idea of genetic control of
vector-borne diseases has origins nearly 40 years old, but it was after the advancements
in molecular experiments in the germline of Drosophila melanogaster in the 1980s that a
reevaluation of the idea emerged (ALPHEY et al. 2002; CURTIS 1968). A committee of
the World Health Organization's Special Program for Research and Training in Tropical
Diseases (WHO/TDR) members in Geneva in 1991 established three parameters to be
met before field-testing of any genetically modified mosquitoes (GMMs) could begin.
First, the genetic engineering tools for use with malaria vectors had to be established;
second, effector genes that would block parasite transmission should be determined and
characterized; and lastly, effective methods of dispersing and fixating these effector
genes in a wild population must be realized. An effector gene can function by either
interfering with parasite development or eradicating them completely inside their host.
Added to these parameters is the fact that any modification cannot pose a significant
fitness load such that the GMMs would not survive as well as wild mosquitoes in a
natural setting.
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The last decade has shown considerable progress in the genetic manipulations of
anopheline mosquitoes. The P. falciparum and An. gambiae genomes were both
completed in 2002 (GARDNER et al. 2002; HOLT et al. 2002) and effector genes whose
products can hinder parasite development in the mosquito are continually being
identified. Because the parasite has to cross two different epithelial layers, it has been
suggested that specific interactions exist between Plasmodium surface proteins and
different molecules on the surfaces of the epithelial layers. Blocking these interactions
could result in effective reduction of malarial transmission.
Certain effector proteins have been shown to inhibit parasite development in the
mosquito gut (ITO et al. 2002; MOREIRA et al. 2002b; MOREIRA et al. 2004). A
dodecapeptide named SM1 (Salivary gland and Midgut peptide 1) was identified through
a phage display library designed for phages that bind to both the midgut and salivary
gland epithelia (GHOSH et al. 2001). An. stephensi carrying transgenic E. coli that both
display SM1 on the surface of their outer membranes and secrete the peptide into the
midgut lumen have been shown to reduce P. berghei invasion by 41% (RIEHLE et al.
2007). Until recently, the mechanism by which SM1 inhibits Plasmodium sporozoite
invasion of the salivary glands was not known. It has now been shown that SM1 is a
conformational analog to the Plasmodium protein TRAP (thrombospondin-related
anonymous protein) and it competes with TRAP in binding to the salivary gland protein,
saglin (GHOSH et al. 2009). Sporozoites of all Plasmodium species express TRAP and
this protein is needed for sporozoite gliding and invasion of mosquito host cells (SULTAN
et al. 1997). Ghosh et al. (2009) have shown that the SM1 peptide and the A-domain of
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TRAP both bind to saglin, a protein expressed in the salivary gland distal lobes, which is
precisely the site of sporozoite invasion (BRENNAN et al. 2000).
Another effector protein identified was a phospholipase isolated from both
honeybee and snake venoms called PLA2 (ABRAHAM et al. 2005; MOREIRA et al. 2002b;
ZIELER et al. 2001). PLA2 purified from the venom of the eastern diamondback
rattlesnake (Crotalus adamanteus) was shown to inhibit oocyst formation in both avian
and human malarial parasites (P. gallinaceum and P. falciparum, respectively) when
administered to Aedes aegypti, An. stephensi, and An. gambiae mosquitoes following an
infectious blood meal (ZIELER et al. 2001). Honeybee venom PLA2 was expressed by
An. stephensi and detected in the midgut epithelia 8-24 h after a blood meal. Importantly,
PLA2 was shown to inhibit P. berghei oocyst formation by 87% and greatly reduce
transmission of the parasite to uninfected mice (MOREIRA et al. 2002b). E. coli
expressing honeybee PLA2 inside the mosquito gut also caused a 23% reduction in
P. berghei development (RIEHLE et al. 2007). It is hypothesized that phospholipases of
this class block a specific receptor in the midgut epithelial lining and hamper the
parasite’s mobility through this layer.
Pbs21 is a 21 kDa protein found on the surface of the ookinete stage of the rodent
malarial parasite P. berghei. Mouse monoclonal antibodies have been made against this
protein and shown to prevent development from gametocytes to oocysts (YOSHIDA et al.
1999). Yoshida et al. constructed a gene for a single-chain antibody (scFv) by cloning
the genes encoding the variable light and heavy chains of the antibody and assembling
them into one open reading frame. This Anti-Pbs21 scFv was shown to bind to the
surface of P. berghei ookinetes and blocked oocyst formation in the mosquito gut by 93%
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(YOSHIDA et al. 1999). In place of genetically engineered anophelines, E. coli expressing
the Anti-Pbs21 scFv were introduced into the gut of An. stephensi mosquitoes by
membrane feeding. The overall number of infected mosquitoes and their oocyst densities
were lowered when the mosquitoes were allowed to feed on P. berghei-infected mice
(YOSHIDA et al. 2001). These experiments helped to support the idea of utilizing
genetically engineered bacteria in the mosquito gut to fight Plasmodium development and
transmission.
Another example of an anti-Plasmodium effector protein is the CEL-III lectin
isolated from the body fluid of the sea cucumber, Cucumaria echinata, has hemolytic and
cytotoxic activity against human and rat erythrocytes. This protein rapidly creates holes
in the erythrocyte cell membrane (HATAKEYAMA et al. 1995). It is thought that CEL-III
is part of the innate defense system of the sea cucumber. Yoshida et al. (2007)
hypothesized that with CEL-III present in the mosquito gut during a blood meal, rapid
hemolysis would occur and thus the gut environmental conditions would be altered in a
way that would inhibit Plasmodium development. In addition, it was discovered that
CEL-III could bind to ookinetes and thus prevent sporogonic development. Experiments
revealed a severe impairment of the rodent malarial parasite P. berghei and a moderate
blockage of the human parasite P. falciparum (YOSHIDA et al. 2007).
Experiments involving GMMs appear promising in the laboratory setting, but the
fitness and fecundity of these insects will have to equal or exceed that of wild mosquito
populations if they are to be fixed successfully in the wild. In five independent
laboratory experiments, transgenic mosquitoes expressing PLA2 showed 77-99%
inhibition of oocyst formation (MOREIRA et al. 2004). As compared to nontransgenic

11

mosquitoes, the PLA2 transgenics consistently showed lower numbers of sporozoites in
salivary glands. Additionally, PLA2 transgenics showed a significantly lower fecundity
and ingested 10-50% less blood than nontransgenics (MOREIRA et al. 2004). Through a
series of cage experiments whereby transgenics and nontransgenics coexisted in the same
enclosure and were maintained blindly over five generations, it has been shown that
transgenics expressing SM1 showed no significant reduction in fitness as compared to
nontransgenics (ABRAHAM et al. 2005; MOREIRA et al. 2004). Further studies on SM1expressing mosquitoes fed on P. berghei-infected blood revealed that the transgenics
actually had a greater fitness over nontransgenics. Over time the transgenics
outcompeted nontransgenics and were more fit in terms of fecundity and mortality rates
(MARRELLI et al. 2007). What these combined experiments suggest is that the influence
on fitness of transgenics will be dependent upon the protein product of the particular
effector gene analyzed (JACOBS-LORENA 2003).
Before transgenic mosquitoes or bacteria are released into the wild, it is
imperative that attempts are made to understand the effects these organisms may have on
native mosquito populations. One study used two geographically isolated An. gambiae
strains (Mbita from western Kenya and Ifakara from Tanzania) to compare hybrid fitness
to that of the founder populations (MENGE et al. 2005). This study was done in the
laboratory with the intent of mimicking the introduction of an exotic transgenic
anopheline strain to that of a wild population. These scenarios introduce new alleles into
a population in addition to parasite-inhibiting genes. The authors measured traits found
to be important in determining an insect vector’s transmission capabilities: fecundity,
body size, blood meal size, and adult longevity. It was observed that all traits showed
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heterosis (increased fitness in the hybrid strain) over each of the founder populations up
to the 20th generation. Results such as this suggest that transgenic strains introduced to
the wild could become a nuisance by living longer and biting more frequently than
indigenous mosquitoes. Also, greater hybrid fitness could lead to stabilizing selection
that would make it difficult for refractory genes to become fixed in the population. The
authors stress that anopheline strains used to carry transgenes should have very similar
genetic makeup to native populations to curb or eliminate the likelihood of increased
hybrid fitness in the wild.
A major obstacle in utilizing this technology is determining how to effectively
establish the GMMs in the field (RIEHLE and JACOBS-LORENA 2005; RIEHLE et al. 2003).
One method would be to significantly reduce the numbers of endemic mosquito
populations (perhaps through the use of insecticides), and then release of the GMMs on a
large scale. The main problem with using genetically modified mosquitoes is that
generating enough mosquitoes to replace entire populations on a country or continentwide scale is nearly impossible. Alternatively, through the use of transposable elements
as a genetic drive mechanism, a transgenic population could replace a wild population.
However, the effectiveness of this method is not known. Transposable elements could
also pose a significant fitness load on the insects because of the frequency and location of
transposition events resulting in the disruption of genomic organizations and increase in
mutation rates. There is also the possibility that after a certain number of generations, the
insects become refractory to transposition, perhaps due to selection of a repressor protein.
This would be similar to the P (refractory) cytotype in Drosophila melanogaster where
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the accumulation of a repressor protein inhibits transposition and slows the mobility of
the P element (CRAIG 2002).
1.6 Paratransgenesis as a Means to Fight Diseases
There is an alternative to creating expensive and time-consuming genetically
modified mosquitoes in the fight against Plasmodium transmission. The past few years
have seen an increased interest in and application of paratransgenesis, which is the use of
genetically modified bacteria to treat many different diseases and conditions. For
example, paratransgenesis has been effective in a laboratory setting in inhibiting
development of the parasite that causes Chagas disease, which is vectored to humans by
blood-feeding insects (DURVASULA et al. 1997). Paratransgenesis involves genetically
modifying a bacterial species that normally resides in the gut of an insect to produce
functional molecules that will inhibit the development of the parasite vectored by the
insect (ALPHEY et al. 2002; BEARD et al. 1998; BEXTINE et al. 2004). In addition to
inhibiting insect-borne diseases, there are also examples of this approach being used to
reduce HIV infectivity in mammalian cells (CHANG et al. 2003; RAO et al. 2005).
Paratransgenic approaches to limiting the spread of the insect-vectored Chagas
disease have yielded encouraging results. Chagas disease is a parasitic disease in humans
that affects people living in most of Central and South America. It is caused by the
parasite Trypanosoma cruzi, which is vectored by the blood-feeding insect, Rhodnius
prolixus, commonly called the kissing bug. These insects colonize thatched homes that
are common structures in tropical regions and can transmit Trypanosoma to humans who
come in contact with insect feces. Contact can occur when the insect is taking a blood
meal from a human and deposits a fecal droplet on the skin or even when a person
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unknowingly touches their eyes, mouth, or open cuts, with hands contaminated with
Rhodnius fecal matter. Between 12-15 million cases of Chagas are estimated to occur
annually, and approximately 10-30% of cases will progress into a chronic and lifethreatening illness of the cardiac and gastrointestinal systems. Chagas disease causes
about 50,000 deaths each year in tropical America, making it a leading cause of mortality
in these regions (BEARD et al. 2002; BEARD et al. 2001).
The first example of the disruption of insect vector capabilities via the genetic
alteration of endosymbiotic bacteria came in 1997 when an endosymbiont of Rhodnius
prolixus, the actinomycete Rhodococcus rhodnii, was engineered to express cecropin A, a
peptide that is lethal to Trypanosoma (DURVASULA et al. 1997). The recombinant
bacterium was fed to Rhodnius insects and a significant reduction in Trypanosoma
survival inside the insect was observed. R. rhodnii was a prime choice for genetic
modification because it resides in close proximity to Trypanosoma when inside the
insect’s gut. Cecropin A is a small insect immune peptide that creates holes in the
membrane of T. cruzi. Other optimistic observations in this study included the absence of
toxicity to insect tissues due to the presence of the recombinant symbionts and the spread
of these symbionts through a colony due to insect coprophagic (the eating of feces)
behaviors. These researchers have even developed a paste called CRUZIGARD that
contains GM R. rhodnii and mimics Rhodnius fecal matter in composition, which newly
hatched insects will eat and ingest these bacteria early in their development. This gives
the GM bacteria ample time to colonize the insect (BEARD et al. 2002).
Pierce’s disease, a devastating disease that affects grapevines in Southern
California and other parts of the world, which is caused by the pathogenic bacterium,
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Xylella fastidiosa, is another target for paratransgenic therapies. The glassy-winged
sharpshooter (GWSS), Homalodisca coagulata, is the vector for this bacterium.
X. fastidiosa is transferred to the xylem of grape plants while the GWSS feeds on the
leaves. The plants succumb to this pathogen and as a result, the wineries in these regions
can suffer great economic loss. An artificial feeding system can introduce the nonpathogenic bacterium Alcaligenes xylosoxidans denitrificans to the insect through a liquid
medium (BEXTINE et al. 2004). This bacterium was chosen from among other culturable
bacterial species because it was found to be associated with the xylem of plants. It also
resides in close proximity to X. fastidiosa in the foregut of the insect, making it an
optimum candidate for expression of anti-Xylella effector molecules. Successful delivery
and colonization of A. xylosoxidans denitrificans in the foregut of the GWSS suggests
that a paratransgenic approach to combating Pierce’s disease is within reach.
Paratransgenesis is also being used to combat diseases that do not need an insect
vector to infect humans, but the concept of engineering symbiotic bacterial species to
express inhibitory molecules remains the same. Human Immunodeficieny Virus, or HIV,
is a global health epidemic that demands immediate preventative measures. Women are
more at risk for infection due to a greater efficiency of transmission from male to female
(ROYCE et al. 1997). Alternative methods of virus inhibition include engineering bacteria
normally found in the gastrointestinal or cervicovaginal mucosa of mammals to express
anti-HIV inhibitor proteins (CHANG et al. 2003; RAO et al. 2005).
Chang et al. (2003) engineered a natural human vaginal isolate, Lactobacillus
jensenii, to express a secreted form of the HIV-binding protein, CD4. In vitro results
show that the CD4 produced by these cells was able to inhibit HIV-1 entry into target
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cells. The authors believe that these engineered lactobacilli may survive on vaginal
mucosa in vivo for days to weeks at a time, allowing for intermittent administrations of
the bacteria to females at high risk for HIV infection.
Rao et al. (2005) engineered a strain of E. coli called Nissle 1917 to secrete an
anti-HIV fusion peptide. The inhibitor peptide was a 52 amino acid sequence derived
from the C-terminal region of gp41, a transmembrane subunit of the HIV envelope that
works in the mechanism of membrane fusion. The authors observed peptide secretion at
inhibitory concentrations and also observed the ability of the bacterium to
nonpathogenically colonize the gastrointestinal and cervicovaginal tracts of mice for
periods of weeks to months. This genetically modified bacterium proves promising as a
potential treatment for HIV infection in humans.
A proof-of-concept experiment for paratransgenic malaria control involving the
rodent malaria parasite P. berghei, showed its development in An. stephensi mosquitoes
was inhibited 90-95% in the presence of E. coli expressing an Anti-Pbs21 scFv (YOSHIDA
et al. 2001). The Anti-Pbs21 scFv binds to a 21 kDa surface protein on P. berghei
ookinetes, which occur in the mosquito midgut (YOSHIDA et al. 1999). Interestingly, the
control for this experiment, administering E. coli expressing a non-specific scFv to
P. berghei-infected mosquitoes, also resulted in a significant reduction of P. berghei
development (YOSHIDA et al. 2001). There may be an indirect negative effect upon
Plasmodium due to the presence of the E. coli or the presence of an scFv (regardless of its
specificity). However, because E. coli are not naturally found in mosquito guts, and
therefore not adapted to this environment, the use of this bacterium may not be efficient
in a field setting.
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There are many advantages to using paratransgenesis to counter insect vector
competence. If the transgene-carrying bacterium colonizes the same areas inside the
insect as the targeted parasite, the transgene product affecting the parasite is in close
proximity and its effect is increased. Introduction of bacteria into insect populations may
be much easier than transgenes alone. Most bacteria can be transformed with DNA quite
easily and immense quantities of bacteria can be produced with minimal costs. Also,
multiple effector genes can be added to one species simultaneously and if one gene
should lose effect over time, it should be relatively easy to introduce an alternate effector
gene.
The most important factor in using a paratransgenic approach to fight a disease is
the choice of bacterium. Optimally, the chosen bacterial species should be able to be
cultured and genetically manipulated in the laboratory setting. This species must also be
adapted to or indigenous to the environment that the disease of interest occupies. It is
important that the GM bacterium is able to survive, undergo normal cellular operations,
and hopefully even replicate in the environment, otherwise, the GM population will have
to be continually replenished. Replenishment of the GM bacteria may be a difficult task
depending on the disease and its host environment.
1.7 Bacterial Candidates for Paratransgenesis
Certain characteristics of the obligate, intracellular, Gram-negative bacteria called
Wolbachia suggest it could be a powerful drive mechanism for spreading effector genes
through an insect population. This is because these bacteria inhabit the reproductive
systems of arthropods and are maternally inherited. Wolbachia also cause cytoplasmic
incompatibility, which means that females who do not harbor Wolbachia will not produce
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offspring (SINKINS 2004). It has been observed that Wolbachia spread through a
Drosophila simulans population in California at the rate of 100 km per year (TURELLI and
HOFFMANN 1991).
The devastating disease dengue fever, vectored by the mosquito Aedes aegypti,
may one day be curbed by infecting Aedes mosquitoes with strains of Wolbachia that
shorten the life-span of the mosquito (MCMENIMAN et al. 2009). Parasites like
Plasmodium and the dengue flavivirus require a particular length of time inside their
insect host for proper development before they are infective and can be transmitted to a
human. This length of time is about 2 weeks for both dengue fever and malaria. For this
reason, older mosquitoes are of a higher epidemiological importance. The Wolbachia
wMelPop strain was previously shown to limit the life span of adult Drosophila
melanogaster and McMeniman et al. tested to see if a similar effect would be observed in
Aedes mosquitoes (MCMENIMAN et al. 2009; MIN and BENZER 1997). These authors
report Aedes populations were reduced by half with the presence of the life-shortening
Wolbachia wMelPop strain. With further studies under seminatural conditions, the
validity of using Wolbachia to reduce the life span, and thus the infectivity, of Aedes
mosquitoes that carry dengue fever can be assessed.
In the case of malaria, as a cruel twist of fate, Wolbachia is not an option for
mosquito control. Wolbachia has not been observed in anopheline mosquitoes.
Additionally, Wolbachia colonizes the reproductive structures of insects, which is not in
proximity to the gut where Plasmodium undergoes development. Therefore, transgenic
Wolbachia would not be effective in a mosquito control scenario that targets
Plasmodium, as mentioned above.
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Engineering a bacterium that naturally colonizes the gut of the mosquito to
express effective anti-malarial genes would greatly increase the likelihood of inhibiting
the Plasmodium parasite. Plasmodium is most vulnerable within the insect midgut.
Mosquitoes can ingest 103 gametocytes with a blood meal, but less than 10 ookinetes will
successfully traverse the midgut epithelium and form oocysts. Parasite numbers increase
dramatically only after each oocyst produces thousands of sporozoites (GHOSH et al.
2000; RIEHLE and JACOBS-LORENA 2005). Therefore, targeting ookinetes could interfere
dramatically with malarial transmission. Additionally, another advantage of this
paratransgenic approach is that, unlike with the use of insecticides, the condition of the
natural habitat is left intact and the biological niche is filled with mosquitoes that are
incapable of transmitting the malarial parasite.
Adult, blood-fed, female An. stephensi mosquito colonies in the Jacobs-Lorena
laboratory at Johns Hopkins University served as the source for an initial screen for
bacterial species that are both well adapted to the gut environment and that are able to be
cultured in the lab. Isolates were characterized for Gram staining and cellular
morphology, 16S ribosomal DNA sequencing, and resistance to any drug markers (if
any). From this screen, Gram-negative Enterobacter spp., Klebsiella sp., Serratia sp.,
and gram-positive Bacillus spp. were identified (RIEHLE et al. 2007).
Pantoea (= Enterobacter) agglomerans was chosen as a candidate for
downstream applications presented in this dissertation due to its persistence in the
mosquito gut environment, its ability to be cultured in the lab, and because it does not
pose a pathogenic threat to healthy humans. P. agglomerans can also be successively
passed through female mosquito guts to obtain strains that will persist in the gut for
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weeks at a time and who increase their numbers following a blood meal (RIEHLE et al.
2007). Previous studies have shown that P. agglomerans is commonly isolated from wild
mosquito populations and this suggests the insects can readily obtain these
microorganisms from the environment (RIEHLE and JACOBS-LORENA 2005).
P. agglomerans is a rod-shaped Gram-negative γ-proteobacterium that is isolated
from diverse environments, including soil, plants, insects, and humans. Classification of
this species has primarily relied upon sequence comparison of 16S ribosomal DNA and a
handful of protein coding genes (HAUBEN et al. 1998; NAUM et al. 2008; YOUNG and
PARK 2007). Because of the limited phylogenetic analysis, P. agglomerans was
previously designated as Erwinia herbicola or Enterobacter agglomerans until
identification methods became discriminating enough to discern differences in these
species (GAVINI 1989). Classification of this species is quite difficult because the genus
is so diverse, and for this reason careful phylogenetic analysis of as many strains as
possible at one time is important for proper identification. Fluorescence amplified
fragment length polymorphism (FAFLP) has been used to type different strains (BRADY
et al. 2007). This procedure involves a single PCR reaction that amplified DNA to a
concentration that is detectable and sizeable by the laser of an automated sequencer. This
technique is somewhat limiting because the source DNA must be in a pure state and that
is not always possible when analyzing environmental isolates (MORTIMER and ARNOLD
2001). Multilocus sequence analysis (MLSA) has also been used to classify
P. agglomerans strains (BRADY et al. 2008; DELETOILE et al. 2008). This technique
allows for genotyping of a more diverse group of prokaryotes and uses several single-

21

copy protein coding genes in its comparison. As these sophisticated genotyping methods
are more routinely used, proper identification of P. agglomerans strains will continue.
Another newly identified candidate for malarial paratransgenesis is the αproteobacterium, Asaia bogorensis (YAMADA et al. 2000). This species can be cultured
in acidic medium, genetically manipulated, and is associated with the larval and adults
stages of anopheline mosquitoes. Additionally, A. bogorensis has been reported to be
vertically transmitted to offspring, which makes it possible to spread transgenic forms
across mosquito populations (FAVIA et al. 2008). A gfp-expressing strain of
A. bogorensis was shown to colonize the female gut and salivary glands of An. stephensi
(FAVIA et al. 2007). These are the exact locations of Plasmodium development and if
A. bogorensis can be genetically engineered to produce anti-Plasmodium effector
proteins in these locations, a reduction in transmission could be realized.
1.8 Protein Secretion Systems in Gram-negative Bacteria
One caveat of a paratransgenic approach to fight insect-vectored diseases is the
need to deliver the anti-Plasmodium effector product to the exterior of the bacterial cell.
The effector product must be in proximity to its target (i.e. Plasmodium in the mosquito
gut environment) in order to have a negative effect upon its development. By fusing a
DNA sequence encoding a bacterial secretion signal to the effector gene, the gene
product could be exported from the cell upon translation. Currently, there are seven
recognized and characterized secretion system types across all bacterial species, but this
section will focus primarily on the systems utilized in Gram-negative species like the
malarial paratransgenesis candidate, P. agglomerans.
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Gram-negative bacteria have a large and varied arsenal of protein secretion
systems at their disposal. Bacteria export proteins to the extracellular environment in
order to participate in processes like pathogenicity, cell movement or cell-cell
communication, and each secreted protein is linked to a particular secretion apparatus.
Export from the Gram-negative cell involves transport across both the inner membrane
(IM) and the outer membrane (OM) and the different pathways involved in traversing
these membranes can be divided into two categories: Sec-dependent and Sec-independent
(KOSTAKIOTI et al. 2005). Sec refers to the secretion (Sec) translocase, a collection of
proteins that comprise the IM secretion apparatus common to all Sec-dependent secretion
systems (MORI and ITO 2001).
Sec-dependent secretion pathways utilize the Sec translocase for transport across
the IM and different machinery for transport across the OM. Examples of Sec-dependent
secretion systems include Type II secretion systems (T2SS), Type V or autotransporter
secretion systems (T5SS), two-partner secretion (TPS), and the chaperone/usher secretion
system (CU) (KOSTAKIOTI et al. 2005). The Type IV secretion system (T4SS) is
sometimes Sec dependent but is mostly considered Sec-independent (DING et al. 2003).
The T2SS exports proteins in a two-step process. Proteins are first sent across the
IM via the Sec translocase to the periplasmic space, the site of most extracellular protein
folding. Transport across the OM involves several proteins, only one of which is an
integral membrane protein. This protein, Protein D is a secretin and is thought to form
the translocation channel (KOSTAKIOTI et al. 2005). Studies on examples of Type II
secretion in Aeromonas species and of PulA (pullulanase) secretion in Klebsiella oxytoca
have led to the suggestion that the IM and OM constituents make contact with one
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another transiently in the periplasmic space to form a secretion apparatus that spans the
entire cell envelope (LETELLIER et al. 1997; POSSOT et al. 1997). This is believed to be
the case because transport across the OM relies on the proton motive force created in the
IM. Proteins to be secreted by T2SS contain N-terminal secretion signal sequences that
direct them to Sec-dependent translocation across the IM to the periplasmic space. The
signal sequence is removed and the protein is properly folded and further modifications
like subunit assembly can be performed. Finally, the protein is secreted across the OM
by the T2SS secretion apparatus (SANDKVIST 2001). Examples of T2SS include PulA
(pullulanase) secretion in Klebsiella oxytoca and type IV pili formation in Pseudomonas
aeruginosa (NOUWEN et al. 1999; PEABODY et al. 2003). The Out system identified in
Erwinia chrysanthemi is a T2SS that secretes plant cell wall-degrading enzymes,
including PelB (LINDEBERG and COLLMER 1992). This same signal sequence isolated
from Erwinia carotovora has been shown to secrete heterologous proteins in E. coli
(LINDEBERG and COLLMER 1992; THIE et al. 2008; WINTER et al. 1994).
Autotransporter or T5SS is one of the most widely distributed secretion systems
among Gram-negative bacteria and is mostly used to deliver virulence factors that play a
role in pathogenesis. Characteristic of the T5SS is the fact that protein substrates can
mediate their own transport across the OM. Proteins targeted for secretion using this
pathway contain the Sec-dependent N-terminal signal sequence that aids in transport
across the IM as well as a C-terminal β-domain that will insert itself into the OM,
directing export of the internal passenger domain (α-domain) to the cell exterior (JACOBDUBUISSON et al. 2004). Representatives of virulence factors secreted by autotransporter
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include the IgA1 protease of Neisseria gonorrhoeae and the Hap protease of
Haemophilus influenzae (KOSTAKIOTI et al. 2005).
Two-partner secretion (TPS) is very similar to autotransporter secretion and is
found across many different Gram-negative bacterial species. The main distinguishing
component of the TPS system is its accessory protein involved in translocation of the
exoprotein across the OM (JACOB-DUBUISSON et al. 2004). Proteins secreted by this
system are referred to as TpsA proteins and contain both the Sec-dependent N-terminal
signal sequence and a 110-residue N-terminal “TPS domain” that is needed for secretion
across the OM through an integral OM channel-forming protein called TpsB. The TpsA
protein can remain noncovalently bound to the cell surface or released to the extracellular
environment (JACOB-DUBUISSON et al. 2004; KOSTAKIOTI et al. 2005). TPS secretion is
commonly used for the secretion of large virulent proteins including the ShlA cytolysin
of Serratia marcescens and the HMW1A adhesin of Haemophilus influenzae (JACOBDUBUISSON et al. 2004; ST GEME and GRASS 1998).
CU secretion is reserved for the assembly of a superfamily of virulence-associated
surface structures. These include structures involved in adhesion to host cells like P pili
and type I pili of uropathogenic E. coli as well as fimbriae and capsule structures. CU
secretion relies on two proteins that work cooperatively, a periplasmic chaperone and an
outer membrane usher protein (KOSTAKIOTI et al. 2005). As with all other Sec-dependent
substrates, nascent polypeptides are directed to the periplasmic space where they must
interact with a chaperone protein. This chaperone aids in proper folding while preventing
subunit-subunit interactions from occurring prematurely. Chaperone-subunit complexes
interact with the OM usher, and chaperone-subunit complexes are gradually exchanged
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for subunit-subunit complexes, which aids in fiber assembly and secretion to the cell
surface (SAUER et al. 1999).
Sec-independent pathways can export a protein directly from the cytoplasm to the
extracellular space without a stop in the periplasmic space because the translocation
channel spans both the IM and OM. Type I (T1SS) and Type III (T3SS) secretion
systems are categorized as Sec-independent. As mentioned previously, Type IV
secretion systems (T4SS) are usually considered to act in a Sec-independent fashion.
T1SS are used by Gram-negative bacteria to secrete proteins such as pore-forming
toxins, proteases, and lipases directly from the cytoplasm to the extracellular space
without periplasmic intermediates (GENTSCHEV et al. 2002; KOSTAKIOTI et al. 2005).
The mechanism of T1SS is best characterized by the α-hemolysin (HlyA) system of
pathogenic E. coli. Proteins targeted for secretion by a T1SS contain a noncleavable Cterminal signal sequence that sends them to the secretion apparatus. In the case of HlyA,
the C-terminus of the protein acts as the secretion signal. Three proteins form a secretion
apparatus that spans the IM and OM. The IM translocase is comprised of a member of
the ATP-binding cassette (ABC) superfamily (HlyB) and a member of the membrane
fusion protein family (HlyD). An integral OM protein forms a β-barrel with a central
hydrophilic core (TolC). In the HlyA system in E. coli the last 60 amino acids of HlyA
are needed for interaction with the IM translocase, and after this interaction takes place
TolC is recruited via HlyD to form a continuous channel through the cell envelope
(KORONAKIS et al. 1992; WANDERSMAN and DELEPELAIRE 1990).
T3SS utilize an “injectisome” which is comprised of an envelope-spanning
channel and a needle-like projection from the bacterial cell that can make contact with
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and inject virulence factors directly into host cells (CORNELIS 2006). These systems were
first characterized for the Yop proteins of Yersinia pestis and are genetically, structurally,
and functionally related to bacterial flagella. The main component of the bacterial
flagellum, FliC/flagellin, is secreted through the flagellar export apparatus in an identical
fashion to a T3SS (YOUNG et al. 1999).
The T3SS system consists of three types of proteins, proteins that make up the
needle-like projection, the secreted proteins, and regulatory proteins that control the
expression of structural and secreted proteins. Approximately 20 proteins make up the
needle structure and allow for secretion upon contact with the target host cell. For this
reason, T3SS is often referred to as a “contact-dependent pathway” (KOSTAKIOTI et al.
2005). It is not exactly certain what signals are involved in targeting a protein for T3SSmediated secretion. Evidence exists for three different secretion signals. N-terminal
amino acid signal sequences target proteins to be secreted via a T3SS. Additionally, the
signal can also be located in the 5’ of the mRNA molecule for the secreted protein.
Finally, it is possible that a chaperone protein can bind the substrate and direct its
secretion (ALDRIDGE and HUGHES 2001). An mRNA-mediated secretion would result in
a coupling of translation and protein secretion and it is thought that ribosomes in the
process of translating secreted proteins are placed in close proximity with the cytoplasmic
surface of the secretion apparatus. An N-terminal signal sequence would trigger
secretion similar to Sec-dependent secretion pathways, however, the signal is not cleaved
from the mature protein, as it does not make a stop in the periplasmic space. Finally,
chaperone-mediated secretion requires the chaperone to communicate with the secretion
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apparatus. Any substrate that cannot bind to a chaperone will not be secreted (ALDRIDGE
and HUGHES 2001; CHENG and SCHNEEWIND 2000).
It is interesting that different species would evolve the use of different signals to
secrete the same protein. More than one type of secretion signal for the FliC/Flagellin
protein has been characterized in E. coli and Salmonella species. In E. coli, the 5’ UTR
(untranslated region) of the fliC mRNA functions as a protein secretion signal, while the
secretion signal in Salmonella was identified as 22 residues in the N-terminus of the FliC
protein (GAL et al. 2006; MAJANDER et al. 2005; VEGH et al. 2006). Additional and
somewhat conflicting evidence for FliC secretion in E. coli identifies the first 183
residues in the FliC N-terminus as the secretion signal (KUWAJIMA et al. 1989;
MAJANDER et al. 2005).
T4SS are thought to have evolved from bacterial conjugation machinery and have
the capacity to secrete both proteins and single-stranded-DNA-protein complexes directly
into host cells (CASCALES and CHRISTIE 2003). Secretion is carried out through the use
of trans-envelope structures that span the IM and OM and end in a pilus structure at the
surface of the bacterial cell. They are generally considered Sec-independent, but
exceptions like the Sec-dependent secretion of the B. pertussis PT toxin fall under the
category of T4SS (CASCALES and CHRISTIE 2003; KOSTAKIOTI et al. 2005). Most of
what is known about T4SS comes from the T-DNA transfer system of Agrobacterium
tumefaciens. This Gram-negative soil bacterium causes crown gall tumor disease in
plants. It transfers a portion of a plasmid (T-DNA) to the plant cell nucleus, where it is
incorporated into the plant chromosome. Protein localization experiments confirm that
several of the Agrobacterium VirB proteins colocalize with both the inner and outer cell
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membranes and contain periplasmic domains, which suggests that these proteins form an
envelope-spanning channel (CHRISTIE 1997). In addition to the trans-envelope structure,
the secretion system contains a conjugative T pilus structure for delivery of the effector to
the host cell. There are two models for secretion using this pilus structure. The “channel
model” suggests that substrates traverse the OM through the lumen of a pilus-like
structure. The “piston model” proposes a retractile pilus that extends from the cell and
pushes the substrate through the OM pore (CASCALES and CHRISTIE 2003)
Additional Gram-negative secretion systems are continually being discovered.
The Type VI secretion system (T6SS) was identified after researchers reviewed the
organization of gene clusters that encode T4SS-like systems. The original name for these
clusters was IAHP (IcmF-associated-homologous-proteins) because they contained a
gene for an IcmF-like component. IcmF (intracellular multiplication protein F) is an IM
protein that is a known participant in T4SSs (FILLOUX et al. 2008). However, all of the
other genes in the IAHP gene cluster were not homologous to other T4SS genes, leading
researchers to think that a novel secretion system gene cluster had been found (CASCALES
2008; FILLOUX et al. 2008).
The speculative structural model of a T6SS shows the proteins involved forming a
channel that spans both the IM and OM. A protein called VgrG is associated with the
lumen side of the OM and is thought to play a dual role in delivery of the secreted
protein. VgrG may create a puncture in a host cell for injection of the secreted protein
and VgrG may also behave like an autotransporter and carry the secreted protein through
the puncturing device into the host cell (FILLOUX et al. 2008).
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T6SS have been identified in species like E. coli, Salmonella enterica subspecies,
Vibrio cholerae, and usually play a role in virulence and invasion of eukaryotic cells.
Burkholderia mallei, which has four T6SS gene clusters, suggests a redundancy in
virulence or specific systems for use in particular hosts (FILLOUX et al. 2008).
The Gram-positive bacterium, Mycobacterium has revealed a seventh secretion
system (T7SS). Originally called the ESX-1 system, this T7SS is involved in secretion of
virulence factors and conjugation, depending on the Mycobacterium strain (ABDALLAH et
al. 2007). In particular, Mycobacterium tuberculosis encodes five T7SSs. There is no
sequence homology between the components of a T7SS and other secretion systems,
which suggests that this is a novel system. The T7SS is mechanistically unique because
it appears that all of the secreted proteins are co-dependent upon one another for
secretion. Structural data is lacking, but it is thought that a multiprotein complex spans
the Mycobacterium cell envelope similar to type I-IV secretion systems.
T7SS appear to only be utilized in Gram-positive bacteria and have been found in
pathogenic and non-pathogenic species from Corynebacterium and Staphylococcus to
Streptomyces spp. Lots of questions are still being answered regarding the structure and
function of this latest secretion system (ABDALLAH et al. 2007).
Bacteria also use alternate trafficking pathways for shuttling proteins to the IM as
well as the extracellular space that act independent of the Sec machinery. E. coli uses a
SRP (signal recognition particle) pathway that targets specific proteins to the IM, which
is homologous to the eukaryotic SRP pathway that translocates proteins to the
endoplasmic reticulum (DE GIER et al. 1997; VALENT 2001). The prokaryotic SRP is a
ribonucleoprotein complex comprised of a 4.5S RNA and a protein called P48. P48
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binds to the hydrophobic signal sequence in a membrane-bound protein in a cotranslational fashion and targets the nascent protein to a translocon in the IM through its
interaction with a receptor protein FtsY (VALENT 2001). And finally, the Tat pathway
(twin-arginine translocation) is a translocon for sending folded proteins across the IM and
it recognizes a twin-arginine motif at the end of the N-terminal region of the protein
(WEINER et al. 1998). Integral membrane proteins TatA, TatB, and TatC use the proton
motive force across the IM to acquire the energy needed to translocate the protein. It is
TatB or TatC that recognizes the twin-arginine motif in the Tat substrate (PALMER et al.
2005). It was initially thought that the Tat pathway was used mainly to export folded
proteins that bind to cofactors in the cytoplasm, but it has been shown to play a broader
role in delivering virulence factors in several bacterial pathogens (BERKS et al. 2003;
PALMER et al. 2005). Because of its role in virulence, and because there are no
homologues in mammalian cells, the Tat pathway could be a target for antimicrobial
compounds (DE BUCK et al. 2008).
1.9 Applying Secretion Systems to Deliver Heterologous Proteins
Several protein secretion systems have been adapted to deliver heterologous gene
products from the bacterial cell. Frequently, these secretion systems have been shown to
work in E. coli, but other species like Salmonella spp. have also proven to be successful
at secreting heterologous proteins (GEORGIOU and SEGATORI 2005; MERGULHAO et al.
2005). Genetically engineering a bacterium to produce heterologous proteins is much
easier than modifying a eukaryote and it is also more economically viable to produce
large volumes of bacterial cells rather than generate numerous modified eukaryotic
organisms. This section will focus on Sec-dependent (T2SS) and Sec-independent
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(T1SS, T3SS, and SRP) signals that have been used to secrete heterologous proteins from
Gram-negative bacteria.
One of the long-standing technologies for producing large volumes of protein in a
bacterium like E. coli is antibody phage display (CLACKSON et al. 1991). Recombinant
antibodies are valuable tools in biomedical research and therapy. These are often
secreted post-translationally via a Sec-dependent pathway because the antibodies are only
folded correctly when passed through the periplasm. An appropriate leader peptide is
added to the N-terminus of the antibody in order for Sec-dependent secretion to occur.
The most frequently used leader peptide is PelB, from the pectate lyase protein of
Erwinia carotovora (LINDEBERG and COLLMER 1992). It is appealing and convenient to
use this leader peptide because the secretion signal is cleaved from the recombinant
protein in the periplasm and is not part of the finished product. This leader is used in the
human antibody Tomlinson I+J library developed in Greg Winter’s laboratory at the
MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering
(Cambridge, UK), as well as in industrial scale production of human proteins with
medical importance in E. coli (DE WILDT et al. 2000; SLETTA et al. 2004; SLETTA et al.
2007). Commonly, the IPTG-inducible lac promoter drives the expression of the PelBfused passenger protein.
Another frequently used leader peptide is OmpA, from outer membrane protein A
of E. coli (SMITH et al. 2007). This protein is a major component of the outer membrane
and is also secreted in a Sec-dependent fashion. OmpA was tested alongside PelB in the
industrial scale production of human proteins, and was used as the secretion signal in
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phage display constructs (BARBAS et al. 2001; HAIDARIS et al. 2001; SLETTA et al. 2004;
SLETTA et al. 2007).
The E. coli hemolysin system, the prototype of a T1SS, has long been used as a
delivery system for exogenous proteins (FERNANDEZ et al. 2000; HOLLAND et al. 1990b;
TZSCHASCHEL et al. 1996). This system provides genes for the IM channel proteins,
HlyB and HlyD, and a multiple cloning site to accept the exogenous gene upstream of the
coding sequence for the C-terminus (approximately the last 50 amino acids or 23 kDa) of
HlyA. HlyA is the secreted protein in the hemolysin system. The OM-associated protein,
TolC, is usually provided in trans in commonly-tested Gram-negative species (SPRENG et
al. 1999). E. coli has been engineered to secrete at least 400 proteins, from both
prokaryotic and eukaryotic origins, using this pathway and there appears to be no
limitations on the size or origin of the secreted protein (GENTSCHEV et al. 2002).
A Shiga-like toxin was successfully secreted from an attenuated Salmonella
typhimurium vaccine strain using the E. coli hemolysin system (TZSCHASCHEL et al.
1996). In this example, one plasmid provides the hlyB and hlyD genes as well as the
cloning site for fusion to the 3’-end of hlyA (‘hlyA). The IPTG-inducible lac promoter
drives expression of these genes. The authors note that this plasmid is replicated using a
low-copy number ori to eliminate the degradation of the secreted protein as well as to
maintain the stability of the recombinant S. typhimurium clones, but they make no
attempt to prove that the recombinant toxin is functional.
A two-plasmid hemolysin system was shown to work efficiently in E. coli in the
secretion of functional single-chain antibodies (scFvs) (FERNANDEZ et al. 2000;
TZSCHASCHEL et al. 1996). One plasmid carries hlyB and hlyD and the second carries a
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multiple cloning site and the ‘hlyA gene sequence. The IPTG-inducible lac promoter is
also used in these constructs. The reasons the authors give for using the hemolysin
system for production of scFvs over the more widely used N-terminal signal peptide and
Sec-dependent secretion methods are the possible toxic accumulation of scFvs in the
periplasmic space leading to the lysis of cells, as well as clogging of the Sec pathway or
greater outer membrane permeability. The hemolysin system seems like an ideal
alternative to these problems because the product is exported directly to the cell exterior
without a periplasmic intermediate. Fernandez et al. (2000) compared the activity of
scFvs with affinity for transmissible gastroenteritis virus that were secreted by either the
hemolysin system or exported in a Sec-dependent fashion in an ELISA assay. The
authors found that the scFvs had the same binding activity. It is important to note that
active proteins were secreted using the hemolysin system even though there was no stop
in the periplasm, where it is thought that most proteins are correctly folded.
The E. coli flagellar export pathway, which closely resembles a prototypical
T3SS, has been shown to secrete heterologous proteins in E. coli (MAJANDER et al. 2005).
The E. coli flagellar apparatus is a multisubunit protein complex that spans both the OM
and IM of the Gram-negative bacterium with a whip-like flagellum that extends from the
surface of the cell that can propel the cell through its aqueous environment. The exterior
flagellum is made of 14 different proteins and can contain up to 20,000 subunits of the
protein FliC (flagellin) (CHEVANCE and HUGHES 2008). In order to evade host defense
mechanisms, FliC proteins can display antigenic variation by altering the sequence of its
central domain, which is exposed on the filament surface. The N-terminal and C-

34

terminal regions are highly conserved so that the FliC monomers can recognize one
another and polymerize to form the flagellum (YONEKURA et al. 2003).
In the case of E. coli FliC secretion, two different signals have been characterized.
The N-terminus (the first 183 amino acids of the protein) of FliC and the fliC 5’ UTR
were characterized as secretion signals and were used for the secretion of several
different heterologous proteins in E. coli (MAJANDER et al. 2005). The latter is an
important finding because the resultant secreted product is not fused to an endogenous
protein.
Majander et al. (2005) observed the secretion of three different heterologous
proteins (ranging in size from 115-434 residues) under the control of the fliC 5’UTR as
well as an N-terminal FliC fusion with the eukaryotic green fluorescent protein (238
residues). These proteins were secreted in a ΔfliC and ΔfliD (encodes FliD, the flagellum
capping protein) E. coli strain. The yield of secreted product was reported at the mg/L
level, which greatly exceeds yields seen with the hemolysin system (μg/L) (CHOI and LEE
2004).
The SRP (signal recognition pathway) mode of secretion in Gram-negative
bacteria has not been tested extensively for secretion of heterologous proteins. In this
pathway, proteins are secreted co-translationally to the IM and then transported across the
IM to the periplasmic space (VALENT 2001). The N-terminal leader peptides from three
different proteins secreted by the SRP pathway (DsbA (periplasmic protein disulphide
isomerase I), TorT (regulatory protein of TorCAD), and TolB (a periplasmic protein
involved in the TonB-independent uptake of group A colicins) were fused to the coding
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sequence for a soluble antibody fragment and shown to successfully secrete an active
antibody (THIE et al. 2008).
Finally, it is the common perception that laboratory bacterial strains, like E. coli
K12, do not secrete proteins when grown under routine conditions. However, it was
reported that E. coli K12 secretes a small (10.8 kDa) protein called YebF when grown in
the laboratory (ZHANG et al. 2006). The function of YebF and the pathway that secretes
it were unknown upon its discovery in the growth medium, nonetheless the authors saw
this protein as a potential tool for secretion of exogenous proteins. N-terminal amino
acid sequence analysis revealed a 21 residue Sec leader sequence and cellular
fractionation revealed localization of YebF in the periplasm, which altogether suggest a
Sec-dependent secretion pathway (ZHANG et al. 2006).
Three different passenger proteins were fused to the C-terminal end of YebF and
were successfully secreted in an active state. The passengers: human interleukin-2 (15
kDa), α-amylase (48 kDa), and alkaline phosphatase (94 kDa), differ in their sizes and
hydrophobicities, which suggests that YebF-coupled secretion is adaptable to different
proteins (ZHANG et al. 2006). Recently, Athena Environmental Science, Inc. (Baltimore,
MD) patented a YebF secretion kit for use in E. coli indicating the potentially broad
application of this protein in the production of heterologous proteins
(http://www.athenaes.com).
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CHAPTER 2
IDENTIFYING AND APPLYING NATIVE SECRETED
PROTEINS FOR USE IN SECRETION IN PANTOEA
AGGLOMERANS
ABSTRACT
Pantoea agglomerans is a candidate for the paratransgenic control of malaria
because it is routinely isolated from the gut of the anopheline mosquito that transmits this
disease. Malaria is a serious and often fatal disease that affects millions of people around
the world. The genetic manipulation of bacteria to fight diseases is a reasonable
alternative to drug therapies and the genetic modification of eukaryotic disease carriers.
One caveat of this approach is the need to secrete the anti-Plasmodium effector gene
product from the bacterial cell to the mosquito gut environment. It was hypothesized that
the coding sequence of a native secreted protein could serve as the secretion signal. A
search for native secreted proteins was performed using MALDI-TOF to identify 2DPAGE spots isolated from spent growth medium. The corresponding genes were isolated
using a genome walking PCR technique and identified based on homology to sequenced
bacterial species. The best candidate from this search was FliC/Flagellin, which is the
major component of the bacterial flagellum and is known to be secreted from the cell in a
Type III secretion system-like manner. Constructs were made using the P. agglomerans
fliC 5’UTR and the fliC 5’UTR and complete fliC ORF each as the upstream signal for
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secretion of a test protein (an anti-BSA single-chain antibody). These constructs were
based on previously published results showing the fliC 5’ UTR and the N-terminus of
FliC function as sufficient signals for heterologous secretion in E. coli. Attempts to
delete the endogenous fliC gene from the P. agglomerans chromosome using Lambda
Red recombination failed multiple times, which could suggest that this deletion is fatal to
the cell or that the recombination system is non-functional in this species. Overall, these
constructs were not successful in the expression or secretion of the test protein. Reasons
may include the presence of the endogenous fliC gene, or it may simply be that the
flagellar export system in P. agglomerans is not suitable for the secretion of exogenous
proteins.
INTRODUCTION
The number of annual deaths as a result of the anopheline mosquito-transmitted
disease malaria is estimated at 1-3 million people. This is more than the number of
deaths as a result of HIV and tuberculosis combined (BREMAN et al. 2001). The majority
of these cases are young African children. Preventive measures have changed little over
the years: the main strategies are still vector eradication through the use of insecticides
and drugs to combat the parasite in infected people. Both the mosquitoes and the
Plasmodium parasite have evolved resistances to the chemicals, clearly showing that
current strategies are not completely successful (LE BRAS and DURAND 2003). New
approaches to limiting the spread of this disease are desperately needed.
An alternate approach is to render the mosquito an ineffective vector by
genetically engineering it to express anti-Plasmodium proteins. Several effector proteins
that inhibit Plasmodium development in the mosquito have already been characterized
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(ITO et al. 2002; MOREIRA et al. 2002b; MOREIRA et al. 2004; YOSHIDA et al. 2007).
Translating these effectors into practical control reagents, however, has been challenging.
Anti-Plasmodium transgenic mosquitoes have been engineered and shown to hinder
Plasmodium development, but it was a costly endeavor and the tools to drive such genes
into entire wild populations are lacking (GHOSH et al. 2001; MOREIRA et al. 2004;
YOSHIDA et al. 2001; YOSHIDA et al. 2007).
To circumvent the hurdles involved with engineering an insect to express antiPlasmodium effector proteins, a bacterial symbiont of mosquitoes could be engineered to
manufacture the proteins. A prime candidate would be a bacterium well adapted to the
mosquito gut environment, where the gametocyte and ookinete developmental stages of
the Plasmodium life cycle take place. These forms of Plasmodium are key targets for
inhibition of development. The transgenic bacterium could be introduced into a mosquito
population and express the anti-Plasmodium genes while circulating in the gut
environment.
This paratransgenic approach, engineering a bacterial symbiont to produce
antagonistic proteins, could prove to be an efficient tool against the spread of malaria to
humans (RIEHLE and JACOBS-LORENA 2005). This approach has already been shown to
be successful in a laboratory setting in reducing the spread of Chagas disease. This
disease is caused by Trypanosoma cruzi, which is vectored by Rhodnius prolixus
(“kissing bugs”) in parts of Central and South America. Because of the copraphagic
(eating of feces) behavior of these insects, researchers have been able to introduce
genetically modified bacteria to the insects in a paste that mimics adult R. prolixus fecal
matter (BEARD et al. 2002; BEARD et al. 2001).
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In this study, the Gram-negative γ-proteobacterium P. agglomerans, a species
routinely found in anopheline mosquitoes, is a paratransgenic candidate (RIEHLE and
JACOBS-LORENA 2005; RIEHLE et al. 2007; STRAIF et al. 1998). P. agglomerans is
established in the gut microbiota of tephritid flies and locusts and observations suggest a
“moderately mutualistic” relationship (DILLON et al. 2000; DILLON et al. 2002; PELOQUIN
et al. 2002). P. agglomerans has been isolated from diverse environments from plant
material to soil to food preparations, and is not a pathogen in healthy humans (LOIRET et
al. 2004; SCHEIRLINCK et al. 2008). Currently there is no completed genome sequence
for this bacterium, but it is related to E. coli and Salmonella spp. and can be cultured and
manipulated in the laboratory using common molecular biology cloning techniques.
In order to properly target Plasmodium development in the mosquito gut, the
effector protein must be secreted from the bacterial cell. I hypothesized that a native
P. agglomerans secreted protein could act as the secretion signal in an anti-Plasmodium
construct. The proteins secreted by P. agglomerans were precipitated from spent growth
medium by methods similar to those previously published and identified using 2D-PAGE
and MALDI-TOF analysis (CHITLARU et al. 2006; KAZEMI-POUR et al. 2004). Because
of the lack of genome sequence data for P. agglomerans, analysis of the protein profile in
spent growth medium and the subsequent isolation of the corresponding genes was
dependent upon sequence homology to related species whose genomic information is
present in the GenBank database. A genome walking PCR using degenerate primers was
utilized to isolate the secreted protein genes from the P. agglomerans chromosome (GUO
and XIONG 2006).
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In this study, the best P. agglomerans secretion candidate (fliC which encodes
FliC/Flagellin, the main component of the bacterial flagellum) was cloned into vectors
along with the gene for a test protein (a singe chain antibody (scFv) with anti-BSA
activity). Because it was previously reported that the 5’ UTR (untranslated region) of
E. coli fliC was a sufficient signal for secretion, the P. agglomerans fliC 5’ UTR was also
included in some of the test constructs (MAJANDER et al. 2005).
P. agglomerans was unable to express or secrete the anti-BSA scFv test protein
under the control of the fliC 5’UTR or as a fliC-scFv fusion. It should be noted that these
experiments were done in the presence of the endogenous fliC gene because attempts to
delete endogenous fliC from the P. agglomerans chromosome were unsuccessful, which
may indicate that this gene is necessary for viability, or that the Lambda Red
recombination machinery used to delete this gene was nonfunctional in Pantoea species
(KATASHKINA et al. 2009) In conclusion, fliC was not able to be used as a secretion
signal and now further attempts are being made to find an appropriate secretion signal for
use in this paratransgenic candidate.
MATERIALS AND METHODS
Media and Antibiotics E. coli and P. agglomerans were grown in Luria-Bertani broth or
agar (LB). S. cerevisiae cells were grown on YPD agar plates (20 g tryptone, 10 g yeast
extract, 20 g dextrose, 20 g agar per liter) or Minimal Drop-Out Media excluding uracil
(2% glucose) when selecting for yeast recombinants (Sigma Y1501). Final
concentrations of antibiotics (Sigma or Fisher Scientific) were as follows: ampicillin
(Ap), 150 µg/ml; apramycin (Apr) 80 µg/ml; chloramphenicol (Cam), 30 µg/ml;
gentamycin (Gent), 30 µg/ml; streptomycin sulfate (Str), 100 µg/ml; tetracycline (Tc), 15
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µg/ml. Antibiotic stocks were filter-sterilized through a 0.2 µM filter syringe and stored
at -20°C.
Storage of bacterial cells, DNA stocks. All bacterial cell stocks were stored in LB broth
+7% DMSO in 1 ml screw-cap tubes at -80°C. All DNA stocks (plasmid or genomic)
were kept on ice during usage and stored at -20°C when not in use.
Growth of cells in preparation for bulk protein precipitation. A freshly streaked
P. agglomerans colony was used to inoculate 50 ml of LB broth and was grown
overnight (16h) at 250 rpm, 30°C. Thirty milliliters of this culture was used to inoculate
3 L of LB and was grown to late-log phase (approximately 8 h, see Appendix 2 for
growth curve of wild-type P. agglomerans). The cells were removed by two sequential
centrifugation steps at 10,000 x g, 4°C for 15 min. The spent medium was carefully
transferred to a clean flask and trichloroacetic acid was added to a final concentration of
10%. The flask was set on a slow rocking platform and incubated overnight at 4°C.
After centrifugation (12,000 rpm, 4°C, 30 min), the protein precipitate was washed with
copious amounts of very cold 95% ethanol and allowed to dry for several minutes on the
benchtop. The precipitate was collected directly in approximately 200 μl of isoelectric
focusing buffer (8M urea, 2% CHAPS, 50 mM dithiothreitol, 0.2% (w/v) Bio-Lyte® 3/10
ampholytes, trace bromophenol blue (BioRad)) using vigorous pipetting and stored at 20°C (CHITLARU et al. 2006).
Isoelectric focusing and 2D-PAGE. Isoelectric focusing was performed using the
BioRad Protean® IEF cell. Briefly, 11 cm pH 3-10 strips were passively rehydrated with
185 μl of precipitated protein (volume = full capacity of the strip) overnight at room
temperature. The focusing program contained three steps: 250 V for 20 min with a
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linear ramp; 8,000 V for 2.5 h with a linear ramp; and finally 8,000 V for 20,000 V-hr
with a rapid ramp. Total running time was approximately 5.3 hr or 30,000 V-hr. The
strip was equilibrated for 2D-PAGE with a 10 min incubation in 6 M urea, 2% SDS,
0.375 M Tris-HCl (pH 8.8), 20% glycerol, 2% dithiothreitol and a 10 min incubation in
6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 20% glycerol and then placed across the
top of a 10% acrylamide Tris-Glycine gel and subjected to 200 V for approximately 2 h.
If IEF strips were not used immediately for 2D-PAGE they were stored at -80°C.
MALDI-TOF analysis. 2D-PAGE gels were visualized by silver stain (Pierce 24612,
SilverSNAP Stain Kit II). Spots were cored from the gel using sterile wide-bore pipette
tips and stored in deionized H2O at 4°C until they could be shipped overnight to the
MALDI-TOF facility. In order to increase the amount of protein for each sample to be
analyzed, parallel gels were run and identical spots were combined into one tube
(Appendix 3). MALDI-TOF analysis was done at the Taplin MS Facility at Harvard
Medical School (http://gygi.med.harvard.edu/taplin/). This facility performs in-gel
trypsin digestion of the gel spots, microcapillary LC/MS/MS analysis, and searching of
the NCBI Enterobacteriaceae protein database. When results were obtained from a
sample they were reported in a web-based format that includes the identity of the spot
along with the sequence of the peptide fragments and where they align to a known
protein in the NCBI Enterobacteriaceae protein database (Figure 2.3).
Genome walking PCR. Degenerate PCR primers based on the potential codons for the
peptide fragments identified with MALDI-TOF were used to amplify a small portion of
the corresponding gene from the P. agglomerans chromosome. The PCR products were
cloned using TOPO technology (Invitrogen), sequenced (Big Dye, ABI 3101), and
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additional primers were designed for a nested “genome walking” PCR as described in
Guo and Xiong (2006). A gene-specific primer was paired with each of four arbitrary
primers in a PCR reaction to acquire flanking sequences (Table 2.3). The arbitrary
primers, designed by Guo and Xiang (2006) were designed to have enough degeneracy in
them as to allow the primer to anneal somewhere in the flanking DNA of the sequence of
interest. The initial PCR reaction was carried out in a 100 μl volume containing 20 ng
chromosomal DNA as template, 1 μM each of the specific primer and arbitrary primer,
250 μM dNTPs, Taq polymerase, and 1X buffer (10 mM Tris-HCl (pH 8.8), 50 mM KCl,
1.5 mM MgCl2). The cycling conditions were comprised of two stages: In stage 1, an
initial 95°C for 3 min was followed by denaturation at 95°C for 45 sec, annealing at a
range from 60°C to 47.5°C for 45 sec with a stepwise decreasing gradient of 0.5°C per
cycle, and elongation at 72°C for 2 min for 25 cycles. Stage 2 consisted of 95°C for 45
sec, 50°C for 45 sec, and 72°C for 2 min for 35 cycles. One microliter from the first PCR
was used in a second 50 μl volume reaction with 1 μM of a specific nested primer and of
the same arbitrary primer. Cycling conditions were 95°C for 3 min followed by 35
cycles of 95°C for 45 min, 50°C for 45 sec, and 72°C for 2 min and a final 7 min
elongation step at 72°C. PCR products were resolved on a 1% agarose gel, gel-purified
(Zymoclean), and cloned into pCR®2.1-TOPO using the TOPO system (Invitrogen).
Approximately 300 ng of the recombinant TOPO plasmid and 0.1 μg of the M13 Forward
(-20) or M13 Reverse primer were used in a fluorescent dye-labeled dideoxynucleotide
sequencing reaction (BigDye, ABI 3101). This process was repeated, generating new
specific primers as more gene sequence was identified until the characterized sequence
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encompassed the entire ORF and intergenic sequence up to and including the neighboring
genes.
“Recombineering” to delete the P. agglomerans fliC gene from the chromosome. In
order to remove the fliC ORF, 60-mer oligos (Ent deltaFliC Left and Ent deltaFliC Right,
Table 2.3) with 40 bp of homology to the DNA sequence directly flanking the ORF were
designed to amplify the KanR cassette from pKD4 (DATSENKO and WANNER 2000).
After amplification of the cassette using Pfx polymerase (Invitrogen), residual plasmid
template was digested by adding DpnI directly to the PCR reaction and incubating at
37°C for 1 h. The cassette was agarose gel-purified (Zymoclean) and eluted in 20 μl of
deionized H2O.
P. agglomerans was electro-transformed with either 10 ng of pIJ790, pSIM5,
pSIM7, or pSIM9 (Table 2.2) at 1.8 kV in a 0.1 mm cuvette. Electro-transformed cells
were grown in a shaking incubator (250 rpm) for 1 h at 30°C in 1 ml of LB broth and
then plated on selective LB agar and incubated overnight at 30°C. Before using these
cells in a recombineering experiment, PCR was performed to ensure presence of the
plasmid (a portion of the cat gene was amplified from the plasmid). Fifty milliliter
cultures of P. agglomerans cells expressing a Lambda Red plasmid were grown at 30°C
in LB broth containing selective antibiotics and 10 mM L-arabinose until an OD600 of 0.6
was reached. The cells were removed from the media and washed twice in 50 ml of very
cold 10% glycerol. The remaining pellet of cells was resuspended in the drop of
remaining 10% glycerol and 50 μl was transferred to a 0.1 mm cuvette and transformed
at 1.8 kV with 100-300 ng of KanR cassette. After incubating the cells in a shaking
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incubator (250 rpm) for 1 h at 30°C, different amounts were plated on LB agar plates
containing kanamycin and incubated 24-48 h at 30°C.
P. agglomerans that grew on LB Kan plates were picked and assessed for
successful fliC deletion. This was done using the different combinations of fliC and KanR
primers that are listed in Table 2.3 and shown in Figure 2.7.
Plasmid construction. The plasmids in this study were constructed using a yeast gap
repair method (SHANKS et al. 2006). Briefly, the vector to be modified was digested with
restriction enzymes and treated with calf intestinal phosphatase according to
manufacturer’s directions (New England Biolabs). DNA inserts were amplified with
oligos that contained 40 bp of homology to the digested vector (up to 2000 bases from the
digestion site). Agarose gel-purified vector (~20-200 ng) and inserts (50-500 ng), along
with herring sperm DNA (100 μg) were co-transformed into 8-10 large colonies of
S. cerevisiae INVSc-1 (Invitrogen) cells, harvested directly from a YPD plate and
resuspended in 500 μl of PLATE solution (50% PEG, 100 mM LiAc, 10 mM Tris, pH
7.4, 1 mM EDTA). The cells were incubated on the benchtop for ~2 d. After heat shock
at 42°C for 30 min, the yeast cells were resuspended in 150 μl of deionized H2O and
plated on uracil drop-out medium (6.7 g/L yeast nitrogen base minus amino acids, 1.92
g/L yeast synthetic drop-out media supplement without uracil, 2% glucose (w/v) and 20
g/L bacteriological agar) and incubated at 30°C for up to 2 d. Total yeast DNA was
purified from the colonies using the “Yeast Smash and Grab DNA Miniprep” protocol
(ROSE et al. 1990). Fifty nanograms of total yeast DNA was transformed into an
appropriate strain of E. coli and bacterial clones were verified for the resultant plasmid by
restriction enzyme digestion and DNA sequencing.
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The yeast-replicating vector, pDB14, was built as follows. pACYC184 was
digested with XmnI for 1.5 h followed by treatment with calf intestinal phosphatase for 1
h at 37°C. The 2 μm ori and URA3 gene from the yeast cloning vector pMQ64 were
amplified as a single PCR product with 60-mer oligos that contained 40 bp of homology
to the site of insertion in pACYC184 (CHANG and COHEN 1978; SHANKS et al. 2006).
To make pDB19, pDB14 was digested with HindIII and EagI and the inserts (fliC
5’UTR from P. agglomerans and the anti-BSA scFv ORF from pIT2-scFv) were
amplified with 60-mer oligos that contained 40 bp of homology that targeted the
amplicons to recombine with pDB14 near the restriction sites. pDB19 allows for
expression of the anti-BSA scFv under the control of the P. agglomerans fliC promoter.
Similarly, pDB20 was made using pDB14/HindIII-EagI as the vector and the fliC
5’UTR and fliC ORF (as one amplicon from P. agglomerans genomic DNA), and the
anti-BSA scFv gene from pIT2-scFv as the inserts. pDB20 allows for expression of the
fusion protein FliC-anti-BSA scFv under the control of the P. agglomerans fliC promoter.
pDB22 was made by digesting pDB19 within the fliC 5’ UTR using EcoNI and
replacing the UTR with the Ptac promoter from pMALTM-cRI (New England Biolabs)
using yeast gap repair. With this plasmid, the expression of anti-BSA scFv was under the
control of the Ptac promoter and acted as a negative control for protein secretion.
pDB24 was made by digesting pDB14 with HindIII-EagI and recombining in the
P. agglomerans fliC 5’UTR with an AscI site at the 3’ end, and the 6His and myc
epitopes and stop codon from pIT2-scFv. With pDB24, the unique AscI site allows for
the cloning of genes downstream of the P. agglomerans fliC promoter. Then, pDB27
was constructed by digesting pDB24 with AscI and recombining in the malE and scFv
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ORFs. pDB27 allows for the expression of the fusion protein MalE-anti-BSA scFv under
the control of the P. agglomerans fliC promoter.
Finally, the fliC 5’UTR in pDB27 was replaced by digesting the vector with
EcoNI and recombining the Ptac promoter from pMALTM-cRI to make pDB28. With
pDB28, expression of the MalE-anti-BSA scFv fusion protein under the control of the
Ptac promoter serves as a negative control for secretion.
Plasmid maps (Figure 2.6) were made using the free program XPlasMap available
from http://www.iayork.com/XPlasMap/.
Protein preparations and Western Blot analysis on P. agglomerans pellet and spent
growth medium samples. P. agglomerans was electro-transformed with 10 ng of a fliC
secretion construct (1.8 kV, 0.1 mm cuvette) and incubated in a shaking incubator for 1 h
at 30°C before plating on selective LB agar and incubating overnight at 30°C. A fresh
colony was used to inoculate a 5 ml overnight culture in selective LB broth. Pellet and
spent growth medium samples were harvested from the overnight cultures and separated
using sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE).
Specifically, 100 μl of overnight culture were centrifuged to pellet the cells
(10,000 rpm, 30 sec). Seventy-five microliters of the supernatant was transferred to a
new tube containing 25 μl of 3X Laemmli sample buffer (BioRad 161-0737). The
remaining pellet was resuspended in 100 μl of 3X Laemmli sample buffer and all of the
samples were boiled for 10 min before resolving on a 4% stacking and 10% separating
acrylamide gel. Proteins were transferred to polyvinylidene difluoride membrane
(PVDF) in a standard Western Blot transfer apparatus (BioRad) with 10% methanol in
the transfer buffer (95V, 350 mA, 75 min). The membranes were blocked in Tris-
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buffered saline (1X TBS, 10 mM Tris, 150 mM NaCl, pH 7.4) containing 1% (w/v)
bovine serum albumin (BSA) for 3 h at room temperature. For immunodetection of myctagged proteins, membranes were incubated overnight at 4°C with α-myc Ab (1 μg/10 ml
or 1:10,000; Invitrogen 46-0603) diluted in the blocking buffer. After four 15 min
washings in 1X TBS/0.05% Tween-20, the membranes were incubated in stabilized goat
anti-mouse HRP-conjugated secondary antibody (0.01 μg/100 ml or 1:100,000; Pierce
1858413) for 1 h at room temperature. The washing steps were repeated and the bound
antibody-HRP conjugate was detected using a chemiluminescent reaction (SuperSignal
West Femto Maximum Sensitivity Substrate; Pierce 34095) and autoradiographic film.
Nickel column purification of 6XHis-tagged proteins from P. agglomerans cell
lysates and clarified overnight supernatants. To concentrate any 6XHis-tagged antiBSA antibodies present in the P. agglomerans cells or overnight supernatants, a smallscale nickel column purification was performed using a kit from Pierce (B-PER® 6XHis
Fusion Protein Spin Purification Kit 78300) and the eluates were assayed by either
Western blot or ELISA as described.
Enyzyme-linked immunosorbent assays (ELISAs) using spent growth medium from
induced E. coli or P. agglomerans. The activity of the secreted anti-BSA scFv was
tested using an ELISA assay. For each sample analyzed, duplicate MaxiSorp wells
(Nunc) were coated with 100 μl of bovine serum albumin (2 mg/ml) along with two
negative control wells, one coated with 100 μl of 1X PBS and one empty well. The plate
was stored at 4°C overnight (approx. 12 h). Each well was washed three times with 200
μl of 1X PBS before blocking for 2 h at room temperature with 2% dry milk in 1X PBS.
The wells were washed three times with 200 μl of 1X PBS and 100 μl of clarified spent
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growth medium from an overnight culture was added to each well and left to incubate for
1 h at room temperature. The wells were then washed eight times with 200 μl of 1X
PBS/0.1% Tween-20. A α-myc-HRP antibody diluted in blocking reagent (1:2000,
Roche 11-814-15-0001) was added to the wells and left to incubate for 1 h at room
temperature. A second set of eight washes was performed before the α-myc-HRP
antibody was detected using 50 μl/well of the chromogenic substrate 1-Step Ultra TMB
(3,3’ 5,5’-tetramethyl benzidine, Pierce 34028). When a sufficient blue-colored signal
was reached (anywhere from 10-45 min), the reaction was stopped with the addition of
50 μl of 2 M H2SO4 and the absorbance was read at 450 nm with the background
subtracted at 650 nm in a BioRad 3550 plate reader.
RESULTS
2D-PAGE and MALDI-TOF analysis of P. agglomerans spent growth medium.
Large-scale cultures (3 L) of P. agglomerans were grown to late-log phase (OD600
~ 0.8) and the cells were removed by centrifugation. Any secreted proteins present in the
medium at that time were precipitated using trichloroacetic acid and samples were
resolved by 2D-PAGE and visualized using silver stain. Figure 2.1 shows a
representative silver-stained acrylamide gel with the secreted proteins present in a latelog culture. In order to have enough material per spot for MALDI-TOF, parallel gels
were run and identical spots were combined to increase the amount of protein (Appendix
3). In total, sixteen spots were abundant enough for subsequent analysis.
The identity of the highlighted spots (Figure 2.1) was determined by MALDITOF analysis and peptide sequence comparison to E. coli and other related species whose
peptide sequence data was present in the GenBank Enterobacteriaceae protein database.
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Table 2.4 shows the match for the sixteen spots tested. Six of the spots did not have a
significant match to any sequences present in the database. The remaining spots that
were identified matched to E. coli proteins, such as OmpA (outer membrane protein),
periplasmic proteins, the intracellular protein Ssb (single-stranded DNA-binding protein),
and various intracellular enzymes. FliC/Flagellin was chosen as the prime secreted
protein gene candidate. Figures 2.2 and 2.3 show the FliC/Flagellin MALDI-TOF results
from the Taplin Biological Mass Spec Facility. FlgL and Ssb were also chosen as
secondary candidates and the information regarding them is located in Appendix 1.
Isolating secreted protein genes based on peptide sequence.
The fliC gene was isolated from the P. agglomerans chromosome using a genome
walking PCR technique (GUO and XIONG 2006). A schematic explaining this technique
is given in Figure 2.5. Figure 2.4A shows the P. agglomerans FliC peptide fragments
that were identified and their relative placement in the E. coli FliC sequence (shown in
green), as well as the site of degenerate PCR primer design (red arrows). The primers
were based on Gram-negative codon usage tables and allowed for as much degeneracy as
possible to ensure a successful amplification of the corresponding DNA sequence
(SAMBROOK and RUSSELL 2001). The sequence of these primers and the series of
universal “walking primers” are given in Table 2.3. PCR products ranging in size from
200-600 bp were cloned using TOPO technology (Invitrogen). The DNA sequences from
these PCR products were used to generate a P. agglomerans fliC contig from which
additional specific primers could be designed and sequential rounds of genome walking
PCR could be performed. This procedure was repeated until the entire P. agglomerans
fliC gene and the flanking DNA up to and including some of the neighboring genes was
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isolated and sequenced (Figure 2.4B). The P. agglomerans fliC gene is 1,287 bp long
and is neighbored by the fliD and fliB genes. There are 336 bases of intergenic DNA
between the 5’ of fliC and the 5’ of the divergently transcribed fliD. The intergenic
region between the 3’ of fliC and the 5’ of fliB is 160 bp long. The sequence was
deposited as GenBank accession number GQ150763.
Attempts to delete the P. agglomerans fliC gene.
The fliC gene was unable to be deleted from the P. agglomerans chromosome.
Trials were performed using four different Lambda Red recombination plasmids in the
hope that one of the host range origins of replication available would be compatible with
this species. When pIJ790 was the source of the Lambda Red genes (exo, bet, and gam),
no P. agglomerans/pIJ790 colonies grew post-recombination with the KanR cassette.
This was attempted twice, with the second trial using a higher concentration of cassette.
Again, no colonies grew after this second attempt.
When the alternate Lambda Red plasmid pSIM5 or pSIM7 was used, there were
also no colonies recovered. When pSIM9 was used, which has 5-8 copies per cell and a
broad host range ori, 3 colonies were recovered. Each of these colonies were tested for
the deletion of fliC using primers that amplify a portion of fliC, a portion of the KanR
gene, and a fusion between the 5’ UTR of fliC and the KanR gene (Figure 2.7). These
results unambiguously show that the cassette recombined into another region of the
chromosome because a portion of the fliC gene was amplified along with a portion of the
KanR gene. No 5’ UTR-KanR product was seen in any of the colonies tested. This
inability to recover P. agglomerans after recombineering is similar to the results seen in
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Pantoea ananatis, where the Lambda Red system was shown to be toxic due to the
simultaneous expression of the exo, bet, and gam genes (KATASHKINA et al. 2009)
Testing for fliC-mediated secretion of a test protein in P. agglomerans.
P. agglomerans transformed with the various fliC secretion constructs were
grown for approximately 16 h in LB broth containing antibiotics and tested for the
presence of the scFv or MalE-scFv or FliC-scFv fusions, depending on the construct, in
the bacterial pellet and/or clarified overnight supernatant by Western blot analysis.
Additionally, clarified overnight supernatant was tested for the presence of an active scFv
antibody against BSA in an ELISA assay. Presence of the proteins in the supernatant
would indicate fliC-mediated secretion.
The Western blot results can be summarized as follows. Cells transformed with
pDB19 (5’ UTR-scFv), pDB20 (5’ UTR-fliC-scFv), or pDB27 (5’ UTR-malE-scFv)
(Figure 2.4) failed to show any protein in the pellet or supernatant samples by Western
blot analysis followed by detection with α-myc antibodies (data not shown, blank film).
A nickel column 6His purification of overnight cell lysates and clarified overnight
supernatants followed by Western blot analysis and detection with α-myc antibodies also
failed to show any proteins present in either sample (data not shown, blank film). The
constructs for negative control of secretion, pDB22 (Ptac-scFv) and pDB28 (Ptac-malEscFv), also failed to show expression of the proteins in the overnight pellet samples (data
not shown, blank film).
DISCUSSION
Malaria is a very serious disease that claims the lives of over 1 million people
every year. New strategies for curbing the spread of this disease from mosquitoes to
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humans are desperately needed. Proposed here is a paratransgenic approach whereby a
bacterial symbiont of the mosquito vector is engineered to express anti-Plasmodium gene
products. To be effective, the product must be secreted from the bacterial cell so steps to
find a native secreted protein for use as the secretion signal were taken.
Secreted protein profile of P. agglomerans
P. agglomerans secreted sixteen proteins that were detectable with silver stain and
reproducible across multiple protein preparations and gels while growing to late-log
phase in standard laboratory culture conditions. It was recommended by the Taplin
Biological Mass Spec Facility that identical silver-stained spots be combined across
multiple gels in order to increase the amount of protein available for MALDI-TOF. And,
if a spot (despite its abundance) was not reproduced across more than one gel, it was
considered an artifact and not chosen for analysis. Overall, there was not much variety in
the types of proteins being secreted and in fact, multiple spots matched to the same
protein in more than one instance. MALDI-TOF analysis was successful in identifying
10 of the spots based on their homology to E. coli. The remaining spots may not have
been abundant enough for peptide sequencing or perhaps they simply had no significant
match to any protein sequence in the NCBI Enterobacteriaceae protein database. These
proteins may be unique to P. agglomerans and could be identified with additional protein
identification techniques.
In the collection of identified proteins, several matched to intracellular or
periplasmic proteins. This could be due to misidentification of the peptide fragments or
simply due to cell lysis during cell growth, or the collection of cells for protein
precipitation from the spent growth medium. Spots A and I (Figure 2.1) matched to a D-
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ribose binding periplasmic precursor and a D-ribose binding periplasmic protein,
respectively (RbsB). Noting the similar migration of these spots in the gel, it is fair to
say that these spots may be isoforms of the same protein. As its name implies, this
protein localizes to the periplasm and is involved in sugar transport through the
membrane and acts as the primary chemoreceptor for chemotaxis (GROARKE et al. 1983).
Spots B and K both matched to OmpA (outer membrane protein A). These two
spots are very close to one another and migrated to the same molecular weight on the gel,
which would suggest covalent modifications of OmpA resulting in different IEF values.
OmpA is a major component of the outer membrane of E. coli and has several roles
including stabilization of mating aggregates in conjugation and acting as a receptor for
bacteriophages (KOEBNIK 1999).
Spot H matched to the intracellular protein Ssb (single-stranded DNA-binding
protein), which is a DNA helix destabilizing protein that is involved in several DNA
processes in the cell, including DNA replication, recombination, and repair (MEYER and
LAINE 1990). Appendix 1 provides information on the isolation of P. agglomerans ssb,
but it was decided that this protein was not a viable candidate for secretion of the test
protein.
Spots M and N were given the vague identities of “putative hydrogenase” and
“short chain dehydrogenase,” respectively. Although no specific gene names were
assigned to them, proteins that fall under these categories are normally intracellular and
are therefore not optimal secreted protein candidates. Hydrogenases are thought to play a
role in hydrogen cycling during fermentative growth while certain dehydrogenases
participate in the metabolism of lipids and steroids (BLATTNER et al. 1997).
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Spots C and O matched to FlgL (flagellar hook-associated protein 3) and could be
an example of degradation products of one protein because while both spots migrated to
roughly the same isoelectric point, spot O is at a higher molecular weight than spot C.
FlgL is a protein that is secreted via the flagellar export pathway and is a component of
the flagellum hook structure (MINAMINO and NAMBA 2004). As explained elsewhere
(Appendix 1), P. agglomerans flgL was not able to be amplified and thus could not be
used as secreted protein candidate.
Finally, spot P matched to FliC (Flagellin), which is the main subunit of the
bacterial flagellum. FliC monomers polymerize end-to-end to form the flagellum (WONG
et al. 2007). FliC is a bona fide secreted protein that is exported by the flagellar export
pathway and was previously shown in E. coli to mediate secretion of passenger proteins
(MAJANDER et al. 2005; MINAMINO and NAMBA 2004). This makes FliC the most
optimal candidate identified from the P. agglomerans secreted protein profile to mediate
secretion of the test protein.
It has also been observed that the secreted proteins visible on a stained acrylamide
gel of the Johns Hopkins mosquito isolate of P. agglomerans used in this study are highly
similar to that of another P. agglomerans strain (“E325” isolated from plant matter)
grown under the same laboratory conditions (PUSEY 2002). The similar 2D-PAGE
profiles infer that secreted protein gene candidates found in the mosquito isolate may
work in the plant isolate to export proteins from the cell. The Lampe laboratory is
currently engineering E325 to produce proteins that will inhibit the spread of Pierce’s
disease. Pierce’s disease may also be controlled using paratransgenic methods. Similar
to malaria, Pierce’s disease is also an insect-vectored disease. A pathogenic bacterium
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called Xylella fastidiosa is transmitted to plant xylem by an insect called the glassywinged sharpshooter (Homalodisca vitripennis, formerly H. coagulata) (REDAK et al.
2004). This results in rapid damage to the grapevines in wineries in California, so there
is an effort in place to control the spread of X. fastidiosa in order to save the wine
industry in this region of the United States (www.piercesdisease.org).
Isolating the P. agglomerans fliC gene sequence
The sequence for P. agglomerans fliC contig (Figure 2.4) was completed after
several rounds of genome walking PCR. The upstream gene is fliD and the downstream
gene is fliB. This is the same genomic organization as seen in E. coli (BLATTNER et al.
1997). In E. coli and Salmonella spp., fliD encodes the flagellum capping protein, FliD.
This cap serves to prevent the FliC subunits from spilling out of the central channel of the
flagellum instead of polymerizing at the flagellum distal end (CHEVANCE and HUGHES
2008; MINAMINO and NAMBA 2004). The gene fliB encodes a lysine methylase, which is
involved in post-translational modification of the flagellum in related species (WONG et
al. 2007). With the complete P. agglomerans fliC sequence determined, secretion
constructs were made to test for the secretion of the anti-BSA antibody.
Failure to delete the endogenous fliC gene from the P. agglomerans chromosome.
A P. agglomerans ΔfliC strain was unable to be made despite the use of several
different Lambda Red recombination plasmids (DATSENKO and WANNER 2000; DATTA et
al. 2006; GUST et al. 2004). Amplification of a portion of the cat gene in the Lambda
Red plasmids (data not shown) confirmed the presence of each of the Lambda Red
plasmids in P. agglomerans transformants. With repeated attempts to electro-transform a
Lambda Red-expressing P. agglomerans with increasing amounts of the Kan cassette and
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still not obtaining transformants, it was hypothesized that a fliC deletion is fatal to the cell
and cannot be recovered.
A recent paper reports that the simultaneous expression of the exo, bet, and gam
genes in a related species, Pantoea ananatis, is highly toxic to the cells and they are not
able to grow into normal-sized colonies on a plate (KATASHKINA et al. 2009). In order to
circumvent this problem and to attain the ability to perform rapid genomic modifications
in this species, the authors screened 106 transformants for mutants that were resistant to
the effects of the Lambda Red proteins. These were colonies that grew to a normal size
on a plate and that then had a similar growth rate in LB broth (before and after induction
of the Lambda Red genes) as compared to Lambda Red control strains (KATASHKINA et
al. 2009). In the experiments reported here, it is uncertain if after induction of the
Lambda Red genes with arabinose toxic levels of the proteins caused the P. agglomerans
cells to die because the OD600 reading of the induced cultures continued to increase over
the 6 h incubation in a fashion similar to a wild-type P. agglomerans culture. Regardless,
recombinant colonies were not recovered on LB agar plates post-recombination.
If this technique were to be tried again, it may be necessary to screen several
Lambda Red P. agglomerans colonies for the ability to grow at a normal rate in broth and
as colonies on a plate after induction of the recombineering genes. If such a strain is
recovered and recombineering is still unsuccessful, longer stretches of homology on the
oligos used to amplify the Kan cassette may increase the chances of recombination
occurring in the exact desired location. Alternatively, instead of deleting the entire gene,
recombination could be performed to insert a point mutation in the fliC coding sequence.
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FliC would be made by the cell and may not result in the inability of the cell to grow, if
indeed, that is the result of a complete fliC deletion.
Testing for the fliC-mediated secretion of a test protein with anti-BSA activity.
The Western blot results obtained in this study do not show expression and/or
secretion of the test protein with any of the constructs tested. Therefore it cannot be
concluded that the P. agglomerans fliC sequence is not a sufficient signal for secretion of
heterologous proteins. Several constructs were tested using the 5’ UTR region of fliC
and the test protein, whether by itself, or as a fusion to FliC or MalE (Figure 2.6). In all
cases, protein expression was not observed let alone protein secretion to the growth
medium. P. agglomerans expressing negative control constructs utilizing the Ptac
promoter to drive expression of the test protein also failed to produce protein.
Future Directions
In order for an anti-Plasmodium strain of P. agglomerans to be effective against
the development of Plasmodium in the mosquito gut, the effector proteins that it produces
need to be exported from the cell. If a native secreted protein cannot be used as the
signal for secretion, then perhaps a heterologous secretion signal that has been well
characterized in related species like E. coli can be used in its stead. Examples include the
Sec-dependent PelB leader peptide from the Erwinia carotovora pectate lyase gene, and
the HlyA (hemolysin A) system from pathogenic strains of E. coli, which is secreted from
the cell by a Sec-independent Type 1 secretion system (HOLLAND et al. 1990a;
KOSTAKIOTI et al. 2005). Both of these signals have been used extensively in E. coli to
produce active secreted protein products (GENTSCHEV et al. 2002; HOLLAND et al. 1990b;
THIE et al. 2008). Because P. agglomerans is a close relative to E. coli, these alternate
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secretion signals should be tested for their efficacy in delivering anti-Plasmodium gene
products to the cell exterior.
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TABLE 2.1 Strains Used in This Study
Strain
E. coli Top10

E. coli Top10 F’
S. cerevisiae INVSc-1
P. agglomerans
P. agglomerans/pIJ790
P. agglomerans/pSIM5
P. agglomerans/pSIM7
P. agglomerans/pSIM9
E. coli BW25113
a

Relevant characteristicsa
F mcrA Δ(mrr-hsdRMS-mcrBC) ø80lacZΔM15
ΔlacX74 recA1 araD139 Δ (ara-leu)7697 galU
galK rpsL (StrR) endA1 nupG
Top 10 with F’[lacIq Tn10 (TcR)]
Sc1: MATa his3D1 leu2 trp1-289 ura3-52
MATα his3D1 leu2 trp1-289 ura3-52
Wild-type strain isolated from Johns Hopkins U.
mosquitoes
Johns Hopkins isolate carrying λ Red plasmid
Johns Hopkins isolate carrying narrow host
range λ Red plasmid
Johns Hopkins isolate carrying broad host range
λ Red plasmid
Johns Hopkins isolate carrying broad host range
λ Red plasmid
lacIq rrnB ΔlacZ hsdR514 ΔaraBAD ΔrhaBAD
-

StrR, streptomycin resistance; TcR, tetracycline resistance
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Source or Reference
Invitrogen Corporation

Invitrogen Corporation
Invitrogen Corporation
(RIEHLE et al. 2007)
This study
This study
This study
This study
(DATSENKO and WANNER
2000)

TABLE 2.2 Plasmids Used in This Study
Plasmid
pACYC184

Relevant Characteristicsa
Cam , Tc ; cloning vector with p15A low copy ori

pMQ64

GentR; yeast recombination vector and source of yeast ori
(2μm) and yeast URA3 gene
ApR; source of malE (maltose binding protein) gene
ApR; source of Ptac
ApR; source of anti BSA scFv with 6His and myc epitopes
CamR; pACYC184/2 μm ori and URA3 gene
CamR; pDB14/P. agg fliC 5’UTR-anti BSA scFv
CamR; pDB14/P. agg fliC 5’UTR-fliC ORF-anti BSA scFv
CamR; pDB14/ Ptac-anti BSA scFv
CamR; pDB14/P. agg fliC 5’UTR-AscI-6His-myc-STOP
CamR; pDB24/P. agg fliC 5’UTR-malE-anti BSA scFv
CamR; pDB14/Ptac-malE-anti-BSA scFv
CamR; source of λ Red recombination genes
AprR; source of oriT-aac(3)IV recombination cassette
KanR; source of FRT-aphII-FRT recombination cassette

pMALTM-c2X
pMALTM-cRI
pIT2-scFv
pDB14
pDB19
pDB20
pDB22
pDB24
pDB27
pDB28
pIJ790
pIJ799
pKD4

R

R

Source or Reference
(CHANG and COHEN
1978)
(SHANKS et al. 2006)
New England Biolabs
New England Biolabs
(WINTER et al. 1994)
This study
This study
This study
This study
This study
This study
This study
(GUST et al. 2004)
(GUST et al. 2004)
(DATSENKO and
WANNER 2000)
(DATTA et al. 2006)

CamR; low copy pSC101 ori, narrow host range λ Red
plasmid
pSIM7
(DATTA et al. 2006)
CamR; broad host range pBBR1 ori, λ Red plasmid
pSIM9
(DATTA et al. 2006)
CamR; broad host range RK2 ts ori, λ Red plasmid
a
ApR, ampicillin resistance; CamR, chloramphenicol resistance; GentR, gentamycin resistance; KanR,
kanamycin resistance; TcR, tetracycline resistance; P. agg, P. agglomerans
pSIM5
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Table 2.3: Oligonucleotides Used in this Study
Oligonucleotide

a

Sequence 5’- 3’a

16S Forward

AGAGTTTGATCCTGGCTCAG

16S Reverse

ACGGCTACCTTGTTACGACTT

M13 Forward (-20)
M13 Reverse
Flagel38-53 For

GTAAAACGACGGCCAG
CAGGAAACAGCTATGAC
GCNAARGAYGAYGCNGCNGGNC

Flagel65-89 For

AGRAAYGCNAAYGAYGGNAT

Flagel65-89 For 2

YTNGCNCARACNACNGARGG

Flagel126-140 Rev

NCCRTTRAAYTGNGTYTGNCC

Flagel582-595 Rev

NACYTGYTGNGGNACYTGRTTNGC

fliC walk to 3’1
fliC walk to 3’2
Semi-1
Semi-2
Semi-3
Semi-4
fliC L1

TTCAGGCAGCGACAACTATG
GATGATGCGACCGGTAAAGTTG
GCCAATTCCGGATNGAYKSNGGNTC
GCCTTAAGGCCTANGARMSNCCNAG
CGGTTAAGGCCTANYTCSKNGANGC
GCCAATTCCGGATNSAGYMNCTNCG
CAATTGCCAACCGTTTCAC

fliC L2
fliC R1

GTAACGCCAACGACGGTATC
AATCAGAGTTGGTGCCGTTC

fliC R2
fliC contig to 3’
gene1
fliC contig to 3’
gene2
fliC contig to 5’
gene1
fliC contig to 5’
gene2
Ent deltaFliC Left

ACAGTCAGCTCACGAACACG
ATTACTGTTGTGGAACCGCTG

Ent deltaFliC Right

ACCCCGCCGAGGCGGGGTTTTGAATTTGCGTT…

fliC 5’ nest 1
k1
k2
kt

GTTAATTCCTTTATAAGGTCG
CAGTCATAGCCGAATAGCCT
CGGTGCCCTGAATGAACTGC
CGGCCACAGTCGATGAATCC

AGCGCTATCTGAAATCCTCAC
TTTTCTGCTTCAGCCTGTCACG
TGTAGCCGCTGAATTACCCTTC
ACACCTTAACCGAAAGACTTGATTAACAGGAAA…

Purpose
To verify P. agg genomic
DNA
To verify P. agg genomic
DNA
Sequencing TOPO inserts
Sequencing TOPO inserts
Amplifying P. agg fliC
fragment
Amplifying P. agg fliC
fragment
Amplifying P. agg fliC
fragment
Amplifying P. agg fliC
fragment
Amplifying P. agg fliC
fragment
Gathering fliC flanking DNA
Gathering fliC flanking DNA
Arbitrary walking primer
Arbitrary walking primer
Arbitrary walking primer
Arbitrary walking primer
Used with arb primers, ΔfliC
check
Used with arb primers
Used with arb primers, ΔfliC
check
Used with arb primers
Nested Genome Walking
PCR
Nested Genome Walking
PCR
Nested Genome Walking
PCR
Nested Genome Walking
PCR
To delete P. agg fliC (70mer)
To delete P. agg fliC (70mer)
Check for deletion of fliC
Check for deletion of fliC
Check for deletion of fliC
Check for deletion of fliC

R = A or G; Y = C or T; N = any nucleotide; K = G or T; M = A or C; S = G or C; P. agg, P. agglomerans
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Figure 2.1: A representative silver-stained 2D-PAGE showing the secreted protein
profile of P. agglomerans. Precipitated secreted proteins from a 3 L late-log culture of
P. agglomerans were separated by IEF (isoelectric focusing) in a pH range of 3-10 in the
first dimension. The proteins were resolved in the second dimension on a 10%
acrylamide gel and visualized using silver stain. The spots circled in blue were analyzed
using MALDI-TOF. Table 2.4 lists the identities of the spots that could be identified.
Appendix 3 shows the additional parallel gels that were generated in order to combine
identical spots for MALDI-TOF.
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TABLE 2.4: Identification of P. agglomerans secreted proteins by MALDI-TOF
Spot
Identitya
A
RbsB (D-ribose periplasmic protein)
B
OmpA
C
FlgL
D
No significant matches
E
No significant matches
F
No significant matches
G
No significant matches
H
Ssb
I
RbsB (D-ribose periplasmic protein)
J
No significant matches
K
OmpA
L
No significant matches
M
Putative hydrogenase
N
Short chain dehydrogenase
O
FlgL
P
FliC/Flagellin
a
Identifications of Spots C, H, and O (FlgL, Ssb, and FliC) are based on protein match
scores as determined by Taplin Biological Mass Spec Facility. See Figures 2.2 (FliC),
A1.1 (FlgL), and A1.3 (Ssb) for scores.
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Figure 2.2 FliC/Flagellin MALDI-TOF Results from Taplin Biological Mass Spec
Facility. Results from MALDI-TOF analysis of each individual spot are viewed by
signing in to the Taplin Biological Mass Spec Facility website with a provided username
and password. In the lower left-hand corner is a menu of protein matches that shows the
number of peptide fragments isolated for this particular spot (8 total). The ID numbers
are a link to an image that shows where each of the peptide fragments align to a known
protein in the NCBI Enterobacteriaceae database. In this case, the peptide fragments
matched to E. coli FliC/Flagellin.
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Figure 2.3: Peptide fragment matches to E. coli FliC/Flagellin from Taplin
Biological Mass Spec Facility. In the case of the spot that matched to E. coli
FliC/Flagellin, eight peptide fragments were generated upon tryptic digestion. This
figure shows where 5 of the 8 fragments matched to the E. coli flagellin protein sequence
present in the NCBI Enterobacteriaceae protein database. The amino acid positions are
given as well as the amino acid sequence of the fragment.
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Figure 2.4: Identity and placement of sequenced P. agglomerans FliC peptide
fragments in the E. coli FliC sequence and the P. agglomerans fliC contig assembled
after genome walking PCR. Eight P. agglomerans FliC peptide fragments were
sequenced using MALDI-TOF and identified based on homology to the E. coli FliC
sequence. Figure 2.4A shows where the fragments (2 fragments are overlapping) match
to the E. coli FliC sequence (residues in green). The red arrows indicate where the
degenerate primers were designed. 2.4B shows the resulting P. agglomerans fliC contig
assembled after genome walking PCR. The blue bracket roughly indicates the length of
sequence obtained.
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Figure 2.5: Genome walking PCR protocol. After a small fragment of DNA was
identified using degenerate primers (top blue box), specific primers were designed on
either end (blue arrows). Flanking sequence could then be obtained by pairing the
specific primers with arbitrary primers in a genome walking PCR reaction. The TOPOcloned and sequenced PCR products can be compiled into a contig that can be made
longer by repeating the process of creating specific primers on the ends of the known
sequence and performing another round of PCR. (Figure adapted from Guo and Xiong
2006).
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pDB19 (6967 bp)

pDB20 (8251 bp)

pDB22 (6967 bp)

pDB27 (8421 bp)

pDB28 (8422 bp)
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Figure 2.6: fliC secretion constructs used in this study. This figure shows the suite of
constructs tested in P. agglomerans for the fliC-mediated secretion of a test protein (the
scFv with anti-BSA activity). These plasmids are yeast recombination vectors due to the
presence of the 2 μm ori and URA3 gene and also contain a bacterial low-copy ori (p15A
ori). The antibody was expressed by itself (pDB19, pDB22), as a fusion to FliC
(pDB20), or as a fusion to MalE (maltose-binding protein) (pDB27, pDB28). Plasmids
pDB22 and pDB28 served as negative controls for secretion because an antibody
expressed under the control of the Ptac promoter would not be secreted from the bacterial
cell. (Plasmid maps were made using the free program XPlasMap available from
http://www.iayork.com/XPlasMap/)
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Figure 2.7: Attempts to delete fliC from the P. agglomerans chromosome were
unsuccessful. A. If the fliC gene was replaced by the aphII gene (confers kanamycin
resistance) using recombineering techniques, then a PCR product (from the primers 5’
nest1 and k1) comprising part of the fliC promoter and part of aphII would be generated.
Concurrently, a portion of aphII would also be amplified (k2 and kt). However, if fliC
was not deleted, and aphII was recombined elsewhere in the chromosome, the only PCR
products generated would be from an interior portion of the fliC gene (fliCL1 and R1)
and a portion of aphII (k2 and kt). B. An ethidium bromide stained agarose gel shows
the results from a fliC recombineering attempt where the aphII gene did not recombine
into the fliC gene as expected, but rather somewhere else in the chromosome. Genomic
DNA was isolated from three separate KanR P. agglomerans colonies postrecombineering (ΔfliC 1-3) and used as the template in three different PCR reactions.
The product from pKD4 serves as a positive control for the k2 + kt PCR reaction. “Pa”
indicates genomic DNA from cells not used in the recombineering experiments as a
negative control template in the PCR reaction.
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CHAPTER 3
USING HETEROLOGOUS SECRETION SIGNALS FOR
SECRETION OF A TEST PROTEIN AND ANTIPLASMODIUM EFFECTOR PROTEINS IN PANTOEA
AGGLOMERANS
ABSTRACT
Malaria originates from the transmission of the parasite Plasmodium to humans
by female anopheline mosquitoes. Estimates put the number of deaths at 1-2 million
people annually and this number will increase without the establishment of new control
strategies. The effectiveness of insecticides and drugs are thwarted by the eventual gain
of resistances for both the insect and parasite, therefore as an alternative, a genetic
engineering approach is presented here. The bacterial mosquito symbiont Pantoea
agglomerans was engineered to express effector gene products that are known to inhibit
Plasmodium development. A caveat of this approach is finding an appropriate protein
secretion signal for export of the effectors from the cell. N-terminal secretion signals
(PelB from Erwinia carotovora, and OmpA and TolB from E. coli) and the C-terminal
signal from E. coli hemolysin A (HlyA) were tested for secretion of a test protein (an
anti-BSA scFv) in E. coli and P. agglomerans. The scFv was secreted from both species
using the PelB and HlyA signals, however it was only active in the case of PelB-induced
secretion. OmpA-induced secretion of the scFv was only seen in E. coli, and the
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antibody was not active. Subsequently, four anti-Plasmodium effector proteins (SM1,
Anti-Pbs21 scFv, PLA2-H67N, and CEL-III) were chosen for secretion and there was
varied expression and/or secretion of the different combinations of secretion signals and
effector proteins in both species. In particular, SM1 appeared to be somewhat toxic to
P. agglomerans as those cultures grew poorly. Additionally, CEL-III-containing
plasmids recovered after cloning contained mutations in the pelB sequence that abolished
transcription, which would suggest that a functional and secretable CEL-III is toxic to E.
coli cells. As a result, this effector was abandoned. The TolB signal was not successful
in secretion of any of the proteins tested in either species. The anti-Plasmodium AntiPbs21-HlyA and PLA2-H67N-HlyA fusions were successfully secreted from
P. agglomerans and these strains are now available for testing inside malaria-infected
anophelines for the inhibition of Plasmodium development.
INTRODUCTION
Malaria is arguably the most prevalent insect-vectored disease on the planet. It is
estimated that 500-700 million people are diagnosed every year and approximately 1-3
million of those will lose their lives to the disease (BREMAN et al. 2001). To curb the
spread and symptoms of this disease, insecticide-treated bed nets and plant-derived
medications can be provided to those in need, but the effects are not a permanent
solution. Eventually, mosquitoes and Plasmodium species will evolve resistances to
these methods. Efforts have been made to genetically modify mosquitoes that can disrupt
Plasmodium development in the gut, but this approach is time-consuming and fitness
costs to the transgenic insect population are a concern (ITO et al. 2002; MENGE et al.
2005). A paratransgenic approach, engineering a bacterial resident of the mosquito gut to
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produce proteins antagonistic to Plasmodium, could prove to be an efficient tool against
the spread of malaria to humans during a blood meal (RIEHLE and JACOBS-LORENA
2005).
Established examples of paratransgenesis include the use of modified bacteria to
fight Chagas disease, a parasitic disease vectored by kissing bugs (Rhodnius prolixus)
that affects people mainly in Central and South America. An actinomycete
endosymbiont of R. prolixus, Rhodococcus rhodnii, was engineered to express cecropin
A, a peptide that is lethal to the Chagas parasite Trypanosoma cruzi. (BEARD et al.
2001). Methods are being developed to spread the transgenic bacteria through an insect
population via a food source for newly hatched insects (DURVASULA et al. 1997).
In addition to insect-borne diseases, there are examples of paratransgenic
strategies to reduce HIV infectivity in mammalian cells (CHANG et al. 2003; RAO et al.
2005). Lactobacillus jensenii, a bacterium normally found in the intestinal and
reproductive mucosa of mammals was engineered to express a secreted form of CD4, an
anti-HIV inhibitor protein. In vitro results showed reduced HIV entry in cultured cells.
Transgenic lactobacilli may survive on vaginal mucosa in vivo for days to weeks, so
routine inoculation of patients at high risk for HIV infection is a possible form of
preventive treatment (CHANG et al. 2003). Additionally, an anti-HIV fusion peptide
expressed by a strain of E. coli was able to colonize the gastrointestinal and
cervicovaginal tracts of mice for prolonged periods and produce the peptide at inhibitory
levels (RAO et al. 2005).
The bacterial candidate for malaria paratransgenesis is Pantoea agglomerans
(formerly Enterobacter agglomerans), a Gram-negative, γ-proteobacterium that is closely
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related to E. coli and Salmonella spp. (GAVINI 1989). The isolate used in this study
originated from adult bloodfed female Anopheles stephensi mosquitoes at Johns Hopkins
University and has been passaged several times through the mosquito to select for
bacteria that will survive for longer periods of time in the gut environment (RIEHLE et al.
2007).
In order to deliver anti-Plasmodium effector proteins to the cell exterior, the
effector gene must be fused to DNA coding for a protein secretion signal. This could
ensure export of the effector protein into the gut environment where it would interfere
with Plasmodium development. Several secretion signals have been used to secrete
heterologous proteins in E. coli. The coding sequences for the first ca. 20 amino acids of
PelB (from the pectate lysase gene of Erwinia carotovora) or OmpA (from the outer
membrane protein A of E. coli), which are secreted from the cell in a Type II-dependent
manner, have been used for heterologous protein secretion in E. coli (LINDEBERG and
COLLMER 1992; SLETTA et al. 2007; THIE et al. 2008; WINTER et al. 1994). The first 20
amino acids of a periplasmic protein involved in colicin uptake (TolB), secreted via the
bacterial SRP pathway, were also used for E. coli protein production (DE GIER et al.
1997; THIE et al. 2008; VALENT 2001). With these secretion signals, the N-terminal
sequence was cleaved from the final product when it was first sent to the periplasmic
space. Finally, the E. coli hemolysin A signal, mapped to the last 60 amino acids of the
protein, has been used to secrete active scFv antibodies in a Type I-dependent manner
(FERNANDEZ et al. 2000; GENTSCHEV et al. 2002; TZSCHASCHEL et al. 1996). The Cterminus of HlyA remains fused to the passenger protein upon secretion.
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The four secretion signals mentioned above were tested for the secretion of a test
passenger protein (scFv with anti-BSA activity) followed by testing for the secretion of
four different anti-Plasmodium effector proteins in E. coli and P. agglomerans. These
included the dodecapeptide SM1 (salivary and midgut peptide 1; PCQRAIFQSICN),
which was discovered in a phage display library and is analogous to the Plasmodium
TRAP protein that is used to invade the mosquito salivary glands and midgut epithelium
(GHOSH et al. 2009; GHOSH et al. 2001). Anti-Pbs21 is a 21 kDa single-chain antibody
that binds to a surface protein of P. berghei and inhibits the developmental transition
from gametocyte to ookinete (YOSHIDA et al. 1999). Phospholipase A2 (PLA2 H67N)
was isolated from honeybee venom, and while its exact anti-Plasmodium mechanism is
unknown, it is believed that intercalation of PLA2 (20 kDa) into the mosquito midgut
lining prevents Plasmodium from traversing this membrane on its migration to the
salivary glands (MOREIRA et al. 2002b). Finally, CEL-III, a lectin isolated from sea
cucumber, was discovered to block the transition from ookinete to sporozoite in both
P. berghei and P. falciparum (YOSHIDA et al. 2007). Previously, E. coli expressing and
displaying SM1, Anti-Pbs21 scFv, or PLA2 H67N on their outer membranes while inside
the mosquito gut have resulted in the inhibition of Plasmodium development, but due to
its inability to thrive for long periods of time in the gut environment, the alternate species
P. agglomerans was chosen for experimentation (RIEHLE et al. 2007; YOSHIDA et al.
2001).
Varying success was found with these secretion signals and effector proteins.
PelB and HlyA directed secretion of the anti-BSA scFv in both species, however it was
only active after PelB-induced secretion. The fusion protein OmpA-Anti-BSA scFv was

78

only expressed and secreted in E. coli and it was not an active protein. Of the antiPlasmodium effectors tested, the PelB-SM1 fusion was expressed but not secreted in both
species. Fusion proteins PelB-Anti-Pbs21 and OmpA-Anti-Pbs21 were expressed and
secreted only by E. coli. PelB-PLA2-H67N was expressed but not secreted by both
species. Finally, Anti-Pbs21-HlyA and PLA2-H67N-HlyA were secreted from both
E. coli and P. agglomerans. The CEL-III lectin gene could not be cloned without the
introduction of mutations in the promoter sequence so it was abandoned as a candidate.
It would appear that the pairing of a secretion signal to a particular effector
protein has to be determined empirically. There are several factors to consider when
attempting to secrete a heterologous protein, including proper protein folding, clogging of
the bacterial membrane translocation machinery, and proteolytic degradation (GEORGIOU
and SEGATORI 2005). Some effector proteins may be produced at levels toxic to some
bacterial species. Other proteins may not be able to be exported via a certain secretion
system due to its size or conformation. Even with all of these factors to consider, the
pursuit of an anti-Plasmodium paratransgenic bacterium should continue. The need for
new measures to fight the spread of malaria remains and a transgenic bacteria approach
could be a cost-effective and efficient means of attack (RIEHLE and JACOBS-LORENA
2005).
MATERIALS AND METHODS
Media Bacteria were grown in Luria-Bertani broth or agar (LB). S. cerevisiae cells were
grown on YPD agar plates (20 g tryptone, 10 g yeast extract, 20 g dextrose, 20 g agar per
liter) or Minimal Drop-Out Media excluding uracil (2% glucose) when selecting for yeast
recombinants (Sigma Y1501). Final concentrations of antibiotics (Sigma or Fisher
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Scientific) were as follows: ampicillin (Amp), 150 µg/ml; apramycin (Apr), 80 µg/ml;
chloramphenicol (Chl), 30 µg/ml; gentamycin (Gent), 10 µg/ml; nalidixic acid (Nal), 30
µg/ml; rifampicin (Rif), 30 µg/ml; streptomycin sulfate (Str), 100 µg/ml; tetracycline
(Tc) 15 µg/ml (unless otherwise indicated). Antibiotic stocks were filter-sterilized
through a 0.2 µM filter syringe and stored at -20°C.
Storage of bacterial cells, DNA stocks. All bacterial cell stocks were stored in LB broth
+7% DMSO in 1 ml screw-cap tubes at -80°C. All DNA stocks (plasmid or genomic)
were kept on ice during usage and stored at -20°C when not in use.
Plasmid construction. The secretion signal plasmids in this study (with the exception of
pDB36 and the HlyA group, Table 3.2) were constructed using a yeast gap repair method
(SHANKS et al. 2006). Briefly, the vector to be modified was digested with restriction
enzymes and treated with calf intestinal phosphatase according to manufacturer’s
directions (New England Biolabs). DNA inserts were amplified with 60-mer oligos that
contained 40 bp of homology to the digested vector (up to 2000 bases from the digestion
site). Agarose gel-purified vector (~20-200 ng) and inserts (50-500 ng), along with
herring sperm DNA (100 μg) were co-transformed into 8-10 large colonies of S.
cerevisiae INVSc-1 (Invitrogen) cells, harvested directly from a YPD plate and
resuspended in 500 μl of PLATE solution (50% PEG, 100 mM LiAc, 10 mM Tris, pH
7.4, 1 mM EDTA). The cells were incubated on the benchtop for ~2 d. After heat shock
at 42°C for 30 min, the yeast cells were resuspended in 150 μl of deionized H2O and
plated on uracil drop-out medium (6.7 g/L yeast nitrogen base minus amino acids, 1.92
g/L yeast synthetic drop-out media supplement without uracil, 2% glucose (w/v) and 20
g/L bacteriological agar) and incubated at 30°C for up to 2 d. Total yeast DNA was
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purified from the colonies using the “Yeast Smash and Grab DNA Miniprep” protocol
(ROSE et al. 1990). Fifty nanograms of total yeast DNA was transformed into an
appropriate strain of E. coli and bacterial clones were verified for the resultant plasmid by
restriction enzyme digestion and DNA sequencing.
PelB plasmid construction. Replacing the bla gene in pIT2-scFv with the aac(3)IV
gene using “recombineering” techniques resulted in pDB36 (DATSENKO and WANNER
2000; GUST et al. 2004). This plasmid allows for the cloning of genes in frame with the
pelB secretion signal and 6His/myc epitope tag sequence in an apramycin resistance
background. Briefly, E. coli BW25113 replicating the Lambda Red plasmid pIJ790 and
pIT2-scFv was grown at 30°C in LB broth containing selective antibiotics and 10 mM Larabinose until an OD600 of 0.6 was reached. The cells were pelleted and washed twice in
50 ml of ice cold 10% glycerol. The cells were resuspended in the drop of remaining
10% glycerol and 50 μl was transformed (1.8 kV, 0.1 mm cuvette) with 500 ng of the
aac(3)IV-oriT cassette from pIJ799. The aac(3)IV gene is flanked by sequence
homologous to the bla gene. After incubating in 1 ml of LB broth in a shaking incubator
(250 rpm) for 1 h at 30°C, different amounts were plated on LB agar plates containing
apramycin and incubated overnight at 30°C.
BW25113/pDB36 transformants were also AmpR (due to pIT2-scFv background)
so a conjugation step was performed to transfer pDB36 into the E. coli recipient LL308.
Plasmid DNA was purified from BW25113/pDB36 and used to transform the donor
strain E. coli ET12567/pUZ8002. An overnight culture of ET12567/pUZ8002 and of
recipient strain E. coli LL308 were grown at 37°C in selective LB broth. On the next
day, 3 ml LB cultures were inoculated with 1/100 dilutions of the overnights and
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incubated until an OD600 reading of 0.4-0.5 was reached (1-2 h). Five hundred microliter
aliquots of the donor and recipient strains were resuspended in fresh LB broth without
antibiotics, combined, and incubated for 20 min at 37°C at a low shaking speed. Then,
the shaking speed was increased and incubation was continued for an additional 1 h.
Varying amounts of the conjugation mixture were plated on LB agar containing nalidixic
acid and apramycin and incubated overnight at 37°C. The resultant colonies were grown
on LB plates containing apramycin or ampicillin to ensure loss of the pIT2-scFv plasmid.
pDB48 contains the pelB secretion signal and the 6His and myc affinity tags
along with a unique AscI site for cloning effector genes in frame between the signal and
tags. The lac promoter drives expression of the resultant protein. To make pDB48,
pMQ64 was digested with HindIII and the entire MCS was replaced with pelB-AscI6His-myc-STOP by yeast recombination. This was accomplished with two inserts, one
containing pelB and the other containing the epitope tags. Both inserts were amplified
from pIT2-scFv using 60-mer oligos that contained 40 bp of homology to the pMQ64 site
of insertion. The left-hand primer for the epitope tags insert contained the AscI
recognition sequence. pDB51 through pDB54 were made by digesting pDB48 with AscI
and cloning in each effector gene as one insert (encoding Anti-BSA scFv, SM1, AntiPbs21, or PLA2 H67N, respectively) using yeast recombination with 60-mer oligos
containing 40 bp of homology to the site of insertion.
OmpA plasmid construction. pDB67 contains the ompA secretion signal and the 6His
and myc affinity tags along with a unique AscI site for cloning effector genes in frame
between the signal and tags. The lac promoter drives expression of the resultant protein.
To make pDB67, pMQ64 was digested with HindIII and the entire MCS was replaced
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with ompA-AscI-6His-myc-STOP by yeast recombination. This was accomplished with
two inserts, one containing ompA (amplified from E. coli genomic DNA) and the other
containing the epitope tags (amplified from pIT2-scfv). Both inserts were amplified
using 60-mer oligos that contained 40 bp of homology to the pMQ64 site of insertion.
The left-hand primer for the epitope tags insert provided the AscI recognition sequence.
pDB69 and pDB71 through pDB73 were made by digesting pDB67 with AscI and
cloning in each effector gene as one insert (encoding Anti-BSA scFv, SM1, Anti-Pbs21,
or PLA2 H67N, respectively) using yeast recombination with 60-mer oligos containing
40 bp of homology to the site of insertion.
TolB plasmid construction. pDB68 contains the tolB secretion signal and the 6His and
myc affinity tags along with a unique AscI site for cloning effector genes in frame
between the signal and tags. The lac promoter drives expression of the resultant protein.
To make pDB68, pMQ64 was digested with HindIII and the entire MCS was replaced
with tolB-AscI-6His-myc-STOP by yeast recombination. This was accomplished with
two inserts, one containing tolB (amplified from E. coli genomic DNA) and the other
containing the epitope tags coding sequence. Both inserts were amplified with 60-mer
oligos that contained 40 bp of homology to the pMQ64 site of insertion. pDB70 and
pDB75 through pDB77 were made by digesting pDB68 with AscI and cloning in each
effector gene as one insert (encoding Anti-BSA scFv, SM1, Anti-Pbs21, or PLA2 H67N,
respectively) using yeast recombination with 60-mer oligos containing 40 bp of
homology to the site of insertion.
HlyA plasmid construction. Replacing the bla gene in pEHLYA2-SD with the
aac(3)IV gene resulted in pDB47. This plasmid allows for the cloning of genes upstream
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of the coding sequence for the C-terminus of HlyA and E-tag epitope in an apramycin
resistance background. To construct pDB47, “recombineering” techniques followed by a
conjugation to eliminate the original plasmid were performed identical to the construction
of pDB36.
To make pDB49, pDB50, and pDB58-60, the vector pDB47 was digested with
NheI/XmaI and treated with a calf intestinal phosphatase according to the manufacturer’s
instructions (New England Biolabs). Each insert (encoding Anti-BSA scFv, MalE-Anti
BSA scFv, SM1, Anti-Pbs21, or PLA2 H67N, respectively) was amplified with 20-mer
oligos that incorporated NheI and XmaI recognition sites on the 5’ and 3’ ends of the
amplicons, respectively. The vector and inserts were agarose gel-purified (Zymoclean)
and eluted in deionized H2O. Ligation reactions containing ~150 ng of vector, varying
amounts of insert (~300-800 ng), and T4 DNA ligase (New England Biolabs) were
incubated overnight (~16h) at 16°C. The reactions were stopped with the addition of 20
μl of deionized H2O and heat inactivation at 65°C for 20 min. One microliter of the
ligation reaction was used to transform the E. coli Top10 recipient strain (1.8 kV, 0.1 mm
cuvette). The cells were incubated at 37°C for 1 h in LB broth and then aliquots were
plated on selective LB agar and incubated overnight at 37°C.
Induction conditions for secretion constructs in E. coli and P. agglomerans.
Individual colonies were used to inoculate 5 ml of LB broth containing antibiotics and
1% glucose (glucose is only needed for E. coli as P. agglomerans is Lac-) and grown at
30°C overnight (12-16 h). On the next day, a fresh 5 ml LB culture containing antibiotics
and glucose was inoculated with 50 μl of the overnight culture and grown to an OD600 of
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0.5. The bacteria were harvested by centrifugation and resuspended in the same amount
of LB broth containing 1 mM IPTG and incubated further at 30°C overnight (12-16 h).
Protein preparations and Western Blot analysis on bacterial pellet and spent growth
medium samples. A 100 μl aliquot from an induced overnight culture of either E. coli or
P. agglomerans was centrifuged to pellet the cells (10,000 rpm, 30 sec). Seventy-five
microliters of the supernatant was transferred to a new tube containing 25 μl of 3X
Laemmli sample buffer (BioRad 161-0737). The remaining pellet was resuspended in
100 μl of 3X Laemmli sample buffer and all of the samples were boiled for 10 min before
resolving on a 4% stacking and 10% separating acrylamide gel. Proteins were transferred
to polyvinylidene difluoride membrane (PVDF) in a standard Western Blot transfer
apparatus (BioRad) with 10% methanol in the transfer buffer (25 mM Tris, 150 mM
glycine, 20% methanol, pH 8.3; 95V, 350 mA, 75 min). The membranes were blocked in
1X Tris-buffered saline + 0.05% Tween-20 (1X TBS: 10 mM Tris, 150 mM NaCl, pH
7.4) containing 1% (w/v) bovine serum albumin (BSA) for 3 h at room temperature. For
immunodetection of myc-tagged proteins, membranes were incubated overnight at 4°C
with an α-myc Ab (1 μg/ml or 1:10,000; Invitrogen 46-0603) diluted in the blocking
buffer. After four 15 min washings in 1X TBS/0.05% Tween-20, the membranes were
incubated in stabilized goat anti-mouse HRP-conjugated secondary antibody (0.01
μg/100 ml or 1:100,000; Pierce 1858413) for 1 h at room temperature. The washing
steps were repeated and the bound antibody-HRP conjugate was detected using a
chemiluminescent reaction (SuperSignal West Femto Maximum Sensitivity Substrate;
Pierce 34095) and autoradiographic film.
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Enzyme-linked immunosorbent assays (ELISAs) using spent growth medium from
induced E. coli or P. agglomerans. The activity of the secreted anti-BSA scFv was
tested using an ELISA assay. For each sample analyzed, duplicate MaxiSorp wells
(Nunc) were coated with 100 μl of bovine serum albumin (2 mg/ml) along with two
negative control wells, one coated with 100 μl of 1X PBS and one empty well. The plate
was stored at 4°C overnight (ca. 12 h). Each well was washed three times with 200 μl of
1X PBS before blocking for 2 h at room temperature with 2% dry milk in 1X PBS. The
wells were washed three times with 200 μl of 1X PBS and 100 μl of clarified spent
growth medium from an overnight culture was added to each well and left to incubate for
1 h at room temperature. The wells were then washed eight times with 200 μl of 1X
PBS/0.1% Tween-20. An α-myc-HRP antibody (1:2000, Roche 11-814-15-0001) diluted
in blocking reagent was added to the wells and left to incubate for 1 h at room
temperature. A second set of eight washes was performed before the α-myc-HRP
antibody was detected using 50 μl/well of the chromogenic substrate 1-Step Ultra TMB
(3,3’ 5,5’-tetramethyl benzidine, Pierce 34028). When a sufficient blue-colored signal
was reached (anywhere from 10-45 min), the reaction was stopped with the addition of
50 μl of 2 M H2SO4 and the absorbance was read at 450 nm with the background
subtracted at 650 nm in a BioRad 3550 plate reader.
RESULTS
The secretion constructs
Figure 3.1A shows the organization of the Type II secretion-based constructs
(PelB, OmpA, and TolB) created for this study. Effector genes were cloned in to a
unique AscI site between the secretion signal and epitope tags. The N-terminal secretion
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signal is directly upstream of the effector gene. The effector protein is tagged with 6His
and myc epitope tags at its C-terminus. The lac promoter drives expression of the ORF.
The plasmid replicates using the broad-host range colE1 origin and confers resistance to
apramycin (aac(3)IV).
Figure 3.1B shows the hemolysin secretion-based construct used in this study.
The effector gene, tagged with 6His and myc at its C-terminus, was cloned by restriction
digestion (NheI/XmaI) between the lac promoter and the 3’ end of hlyA (‘hlyA). There is
also the E-tag epitope available for immunodetection purposes. This plasmid also
replicates using the colE1 origin and confers resistance to apramycin. It must be coexpressed with pVDL9.3, which provides the membrane channel proteins HlyB and
HlyD.
Expression and secretion using the PelB leader
The PelB leader allowed for the expression and secretion of an active anti-BSA
scFv in both E. coli HB2151 and P. agglomerans as shown by Western blot analysis and
ELISA assay (Figure 3.2A and C). The anti-BSA scFv secreted by E. coli is three times
more active than the scFv secreted by P. agglomerans as shown by ELISA assay (Figure
3.2B). The P. agglomerans E325 strain was also able to secrete an active anti-BSA scFv,
although at an even lower level compared to the other strains tested (Figure 3.2A).
Of the three anti-Plasmodium effectors tested for secretion under the PelB leader,
PelB-Anti-Pbs21 was secreted, but only by E. coli HB2151 (Figure 3.2C). PelB-SM1
was expressed by both species, but was not visualized in the spent growth medium
(Figure 3.2C). Finally, PelB-PLA2-H67N was neither expressed nor secreted in either
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species. All of these strains grew at a normal rate before sample collection as compared
to wild-type E. coli HB2151 and P. agglomerans strains.
Expression and secretion using the OmpA leader
The OmpA leader allowed for the secretion of an inactive anti-BSA scFv, but
only in E. coli HB2151 (Figure 3.3). OmpA-Anti-Pbs21 was expressed and secreted in
E. coli, but not in P. agglomerans (Figure 3.3C). OmpA-PLA2-H67N was expressed in
both species, but did not secrete (Figure 3.3C). Finally, OmpA-SM1 was neither
expressed nor secreted in either species. The P. agglomerans OmpA-SM1 strains grew at
a very slow rate compared to the other OmpA strains, so it may be that the OmpAinduced secretion of the SM1 protein was preventing normal growth of the cultures.
Expression and secretion using the TolB leader
The TolB constructs were not successful in the expression or secretion of the
majority of the proteins tested. The only strain to express a protein (anti-BSA scFv) was
E. coli HB2151 carrying the pDB70 plasmid. The anti-BSA scFv protein was made, but
was not visible in the spent growth medium (Figure 3.4C). Despite the inability to detect
the anti-BSA scFv protein via Western blot, a slight amount of activity was detected for
this protein in an ELISA assay, however, the level of activity was not statistically
significant when compared to background levels (Figure 3.4A and B). The
P. agglomerans TolB strains grew extremely poorly and at a very slow rate, however the
E. coli TolB strains grew at a normal rate.
Expression and secretion using the C-terminus of HlyA
The anti-BSA scFv-HlyA construct pDB49 was expressed in E. coli HB2151 and
P. agglomerans. Both species were able to secrete the protein at high levels (Figure
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3.5C), however, neither antibody was active in an ELISA assay (Figure 3.5A). A MalEanti-BSA scFv fusion was made (pDB50) in the hopes that antibody activity would be
restored, but this fusion protein was only expressed in E. coli and was not secreted
(Figure 3.5C).
The anti-Plasmodium effectors Anti-Pbs21 and PLA2-H67N were both expressed
and secreted in high levels as HlyA fusions in E. coli and P. agglomerans (Figure 3.5C).
SM1-HlyA was not expressed or secreted in either species (Figure 3.5C). This does not
seem to be the result of poor growth of the cells, as the cultures grew at a normal rate as
compared to wild-type E. coli HB2151 and P. agglomerans strains.
Difficulties in cloning the anti-Plasmodium effector gene CEL-III
The CEL-III lectin gene from sea cucumber was chosen for expression and
secretion in E. coli and P. agglomerans (YOSHIDA et al. 2007). The CEL-III ORF (1.2
kb) was amplified from pAgCP-CEL-III (Table 3.3) using 60-mer oligos that contained
40 bp of homology for yeast recombination to create pDB55. The yeast strain in which
the recombination took place and the subsequent culture of transformed E. coli Top10
grew similar to other yeast cloning experiments and it was expected that the cloning was
successful. Five E. coli Top10 colonies were checked by restriction digest for the
presence of the recombinant plasmid. All 5 clones contained the recircularized vector. A
second trial of pDB55 yeast cloning was performed and much higher amounts of CEL-III
insert were added to the reaction and the length of yeast incubation time in PLATE
solution was increased to three days. Eight recombinant E. coli colonies were chosen for
restriction digestion and PCR reactions to ensure presence of the CEL-III ORF. Only one
recombinant contained the CEL-III ORF in the resultant plasmid, however, after DNA
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sequencing, it was revealed that a deletion mutation in the secretion signal abolished
transcription of a pelB-CEL-III fusion. Therefore, a functional CEL-III protein would not
be translated nor secreted. Because of this difficulty in cloning and recovering the pelBCEL-III construct, it was abandoned as a candidate for secretion using the other
heterologous signals.
DISCUSSION
The disease malaria claims the lives of millions of people each year. Without the
advent of new and effective preventative strategies this number will certainly rise. The
introduction of a bacterial symbiont expressing anti-Plasmodium gene products into the
mosquito vector could be a targeted method of inhibiting Plasmodium development prior
to transfer to a human host. In order to be effective, the gene product must be delivered
to the cell exterior. Steps to find a suitable secreted protein signal from E. coli for
secretion of anti-Plasmodium effector proteins in the paratransgenesis candidate
P. agglomerans were undertaken in this study.
The suite of anti-Plasmodium effector genes
Four anti-Plasmodium effector genes were available for secretion tests in E. coli
and P. agglomerans. Previously, three of these effectors (SM1, Anti-Pbs21, and PLA2
H67N) were expressed and/or surface-displayed by E. coli while inside the mosquito gut
(RIEHLE et al. 2007; YOSHIDA et al. 2001). Impaired Plasmodium development has been
seen with transgenic mosquitoes expressing CEL-III (YOSHIDA et al. 2007). E. coli has
been used to express fragments of CEL-III for characterization of its functional domains
(KOUZUMA et al. 2003). Expression of the full-length CEL-III gene in E. coli has proven
difficult; the fusion to proteins like thioredoxin are needed to increase yield and
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solubility, and even then the amount of functional and soluble protein made is very small
(Y. Kouzuma, personal correspondence).
With this prior knowledge, it was hypothesized that E. coli and
P. agglomerans could manufacture the SM1, Anti-Pbs21, and PLA2 H67N effector
proteins (8 kDa, 21 kDa, and 20 kDa, respectively, as estimated on a protein gel) without
difficulty. It was hypothesized that the CEL-III protein (47 kDa) might pose a problem
for prokaryotic protein expression and secretion. As will be explained in each of the
following sections, not all of the effector proteins were expressed and/or secreted by
E. coli or by P. agglomerans.
The PelB leader
The PelB leader, isolated from the pectate lyase gene of Erwinia carotovora, is
frequently used as a signal for heterologous protein secretion in E. coli (LINDEBERG and
COLLMER 1992; THIE et al. 2008; WINTER et al. 1994). It was encouraging when E. coli
and P. agglomerans secreted a functional anti-BSA scFv (Figure 3.2), and it was
hypothesized that the anti-Plasmodium effector proteins would behave in a similar
fashion when using this secretion signal. However, the only effector to be secreted, and
only by E. coli, was Anti-Pbs21. SM1 was expressed by both species, but not detected in
the spent growth medium. Encouragingly, there may be explanations for these mixed
results and additional methods that may improve the expression and yield of these
recombinant proteins.
Proteins that are tagged with the PelB leader are secreted from the cell via a Type
II secretion system, which involves passage through the periplasmic space before export
via the Sec translocation machinery present in the outer membrane (OM) (SANDKVIST
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2001). Proteins are folded into their final conformation and the PelB leader is removed in
the periplasmic space (CHOI and LEE 2004). SM1 was detected in the cell pellet but not
in the spent growth medium, so it may have encountered a problem in the periplasm.
This could include periplasmic inclusion bodies, errors in folding or disulfide bond
formation, or degradation (KOLAJ et al. 2009; SCHLAPSCHY et al. 2006). In the case of
Anti-Pbs21, this protein may be toxic or misfolded when made by P. agglomerans,
although this does not seem to be likely because Anti-Pbs21 is an scFv similar to the antiBSA scFv and this protein was secreted by P. agglomerans without any difficulty.
When dealing with difficult proteins destined for the periplasm and beyond, a
group of chaperones that prevent misfolding in the E. coli periplasm, including seventeen
kiloDalton protein (Skp), have been used to improve production, yield, and activity of
scFvs (HAYHURST and HARRIS 1999; MAVRANGELOS et al. 2001). Co-expression of Skp
and an scFv against the herbicide atrazine, whether under the same promoter or on
separate plasmids, increased the amount of soluble and active scFv made by E. coli
(HAYHURST and HARRIS 1999). The yield and activity of two anti-mouse granulocyte
scFvs was improved when the scFv was expressed on a plasmid that also contained skp
(MAVRANGELOS et al. 2001). Mavrangelos et al. (2001) also employed an alternate
Shine-Delgarno sequence upstream of the scFv that resulted in tighter ribosome binding
and enhanced expression.
The oxidizing environment of the periplasm is also the site of disulfide bond
formation, which is carried out by the Dsb (disulfide bond formation) family of proteins
(NAKAMOTO and BARDWELL 2004). DsbA transfers a disulfide bond to the target protein
and is reoxidized by the membrane-bound DsbB. The isomerization of incorrect
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disulfide pairs is carried out by DsbC, which is maintained in an active state by the
membrane-bound DsbD (KOLAJ et al. 2009). Considerable success has been achieved
with the co-expression of DsbABCD and recombinant proteins (JOLY et al. 1998; LEE et
al. 2004; WULFING and RAPPUOLI 1997). This also includes the co-production of Dsb
proteins and glutamate racemase, which has no disulfide bridges in its secondary
structure (KOHDA et al. 2002). As with all of these modifiers, the optimal combination
for each recombinant protein had to be determined empirically.
A helper plasmid containing genes for DsbAC and FkpA and SurA was utilized
for the improvement of secretion of two recombinant secreted proteins in E. coli
(SCHLAPSCHY et al. 2006). These proteins are PPIases, peptidyl-prolyl cis/trans
isomerases that aids in the cis-trans isomerization of petidyl-prolyl bonds in newly
translated polypeptides. This combination of disulfide bond formation proteins and
isomerases could be tested for the improved expression and secretion of all of the effector
proteins used in this study.
It is curious why PLA2 H67N was not expressed by either species, as previous
studies showed expression of this protein in E. coli without incident (RIEHLE et al. 2007).
Because PLA2 H67N was not detected in either species in this study, it may be too
complex of a protein to be expressed in this particular type of construct and then secreted
in a Type II-dependent fashion. Perhaps changing the plasmid origin of replication to a
lower copy ori would help in the production of PelB-PLA2 H67N. It is also worth coexpressing PLA2 H67N with cytoplasmic folding chaperones like DnaK, periplasmic
chaperones like Skp, FkpA, and/or a DsbAC protein to determine if a bottleneck is
reached pre- or post-translocation into the periplasmic space.
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Finally, the addition of thioredoxin, a small 12 kDa protein that participates in
disulfide bond formation, has been shown to improve production of some difficult
proteins that were normally found in inclusion bodies (GARCIA-ORTEGA et al. 2000;
YUAN et al. 2004). Whether as a separate entity or as a fusion to the recombinant protein
(this option is available in a Novagen vector, EMD North America), thioredoxin could
improve production of an effector like SM1, PLA2 H67N, or as mentioned in the
previous section, CEL-III.
The OmpA leader
The OmpA leader has been used to secrete and/or surface display heterologous
proteins from E. coli (EARHART 2000; LANG 2000; SLETTA et al. 2007; THIE et al. 2008).
It was expected that this leader would be useful in secreting the anti-BSA scFv as well as
some of the effector proteins. The opposite was observed. Only E. coli secreted an
inactive OmpA-anti-BSA scFv (Figure 3.3). The Anti-Pbs21 protein was expressed and
secreted by E. coli, as was seen in the case of PelB- and HlyA-induced secretion of this
protein (Figures 3.2 and 3.5), however P. agglomerans was only able to secrete an AntiPbs21-HlyA protein. PLA2 H67N was expressed in both species, but was not detected in
the spent growth medium (Figure 3.3C). As was seen with the previous signals tested,
SM1 was not detected in the cell pellet or spent growth medium.
In the case of the P. agglomerans OmpA-SM1 cultures, the growth rate was
significantly affected by the presence of this construct. Explanations for the loss of
detection of SM1 such as improper folding may not apply in this instance. The fact that
the cultures grew so poorly suggests that the accumulation of SM1 in the cells may have
been too toxic for P. agglomerans to maintain growing. Perhaps the OmpA leader

94

resulted in a jamming of the translocation machinery and the cultures ceased to grow at a
normal rate.
Because recombinant proteins tagged with either the OmpA or PelB leader
peptide are secreted in a similar fashion, the result suggested modifiers in the PelB
section above would apply here. The lack of expression of the anti-BSA scFv, SM1, and
Anti-Pbs21 in P. agglomerans (Figure 3.3C) could be reversed with the introduction of
any of the cytoplasmic chaperones or periplasmic modifiers mentioned above. The lack
of secretion of PLA2 H67N from E. coli and P. agglomerans may be reversed with the
co-expression of the helper plasmid developed by Schlapschy et al. (2006). Again, each
of these options would have to be tested for their efficacy.
The TolB leader
An overall pattern of failure was seen with TolB; it was the least successful in
expression and secretion and also negatively affected the growth of P. agglomerans
(Figure 3.4). TolB, an E. coli periplasmic protein involved in colicin uptake, is secreted
via the bacterial SRP (signal recognition particle) pathway, which translocates proteins in
a co-translational fashion (DE GIER et al. 1997; VALENT 2001). This transport involves
interaction with a ribonucleoprotein complex that shuttles the passenger protein to the IM
Sec translocon and into the periplasmic space before secretion via an OM SRP translocon
(VALENT 2001).
With the exception of detecting the anti-BSA scFv in the E. coli cell pellet, none
of the other proteins were visualized by Western blot in either species. There was a very
faint reaction in the E. coli TolB-anti-BSA scFv ELISA assay, however, the signal
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detected was not statistically significant compared to background readings and was likely
due to technical error during the procedure.
To date, there are few examples of successful SRP-mediated secretion or surface
display of heterologous proteins in the literature (STEINER et al. 2006; THIE et al. 2008).
The SRP pathway may be too esoteric for optimizing secretion of each unique effector
protein, or it may be that a different SRP signal (ex. DsbA or TorT) would be more
successful (STEINER et al. 2006; THIE et al. 2008). Each signal along with each effector
protein would have to be tested empirically.
The E. coli TolB leader may not be recognized by P. agglomerans as a secretion
signal. Conversely, failure to detect expression or secretion may be due to clogging of
the SRP secretion machinery. If so, precursors or altered forms of the proteins would
accumulate and could be detected. This could explain why the cultures grew poorly;
accumulation of aggregated heterologous proteins or the formation of inclusion bodies
would cause the cells to become sick (HOFFMANN and RINAS 2004). Because SRPmediated secretion occurs co-translationally, it is hard to know if the co-expression of
cytoplasmic chaperones and folding catalysts like trigger factor (TF, a PPIase) and heat
shock proteins in the Hsp60 and Hsp70 families (such as the Hsp70 trio DnaJ-DnaKGrpE or the Hsp60 proteins GroEL and GroES, which all act upon newly translated
polypeptides) would improve the yield and delivery of passenger proteins (KOLAJ et al.
2009).
The HlyA secretion signal
Although the anti-BSA scFv test protein fused to the C-terminus of HlyA was
secreted in high levels in both species, neither was active in an ELISA assay (Figure 3.5).
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This could be because fusion to the 30 kDa C-terminus of HlyA abolished function of the
scFv. However, this was not the case for other researchers who secreted functional scFvs
fused to the HlyA C-terminus (FERNANDEZ et al. 2000).
Regardless, HlyA was the most successful of the four signals tested in terms of
delivery of anti-Plasmodium effector proteins to the extracellular space. Both Anti-Pbs21
and PLA2 H67N were expressed and secreted as HlyA fusions by P. agglomerans
(Figure 3.5C). The efficacy of these strains in inhibition of Plasmodium development has
yet to be tested, but in the case of PLA2 H67N (20 kDa), a functional phospholipase is
not needed for inhibition to occur (MOREIRA et al. 2002b). Anti-Pbs21 is a 21 kDa
antibody that binds to a P. berghei surface protein; so proper folding of the protein is
necessary for function (YOSHIDA et al. 1999). It will be interesting to see whether this
scFv can function after being secreted in one step to the cell exterior via this Type I
secretion system and remaining as a fusion to the HlyA C-terminus. As with the Nterminal signals, SM1 (8 kDa) was not detected in the spent growth medium. The fact
that it was not detected in the cell pellet indicates a problem with expression of this
effector protein under these conditions.
The co-expression of a cocktail of cytoplasmic chaperones with PPIase activity
and/or folding properties have shown improvement in the yield, activity, and secretion of
some recombinant proteins in E. coli (DE MARCO 2007; DE MARCO et al. 2007;
NISHIHARA et al. 2000). Trigger factor (TF), a member of the superfamily of cytoplasmic
PPIases and the first chaperone to bind a polypeptide upon its exit from the ribosome,
aids in the cis-trans isomerization of petidyl-prolyl bonds (KOLAJ et al. 2009). This
isomerization is often a rate-limiting step in the folding process and overexpression of TF
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can sometimes improve production of a protein (NISHIHARA et al. 2000). Hsp60s and
Hsp70s are ubiquitous proteins with the ability to aid in folding and trafficking of
polypeptides (KOLAJ et al. 2009). The overexpression of different combinations of
DnaK-DnaJ-GrpE (Hsp70s), GroESL (Hsp60s) and other accessory proteins gave a
considerable boost in the production of soluble heterologous proteins in E. coli (DE
MARCO 2007; DE MARCO et al. 2007).
Activity and solubility of various scFvs were improved after coexpression of
DnaK-DnaJ-GrpE (CHOI et al. 2004; HU et al. 2007). Some of these researchers also
reported a reduced solubility of the scFv after co-overproduction of GroESL, which
provides a warning that certain additives may end up hindering production (HU et al.
2007). It is important to note that in each of these studies different combinations of
modulators worked best for each of the recombinant proteins tested; it is unlikely that a
universal “repair kit” for recombinant production exists (KOLAJ et al. 2009).
Finally, if the HlyA C-terminus fusion reveals itself as a problem, a linker
containing the outer membrane protease OmpT cleavage sequence could be cloned in
between the effector gene and the ‘hlyA sequence (HANKE et al. 1992). Upon secretion,
the effector protein, unencumbered by HlyA, may behave more as expected and go on to
successfully inhibit Plasmodium in the mosquito gut.
Summary
Table 3.4 summarizes the results obtained using the four secretion signals and
four passenger proteins. Overall, the results were mixed and no apparent pattern of
success for one signal or one passenger was seen. Across the board, SM1 was not
secreted using any of the signals and the ompA-SM1 constructs appeared to make
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P. agglomerans cells sick. Anti-Pbs21 was secreted with most of the signals, but only in
E. coli. A protein similar in structure to Anti-Pbs21, the anti-BSA scFv, was secreted as
an active protein in both species, but only under the PelB signal. PLA2 H67N was only
secreted using the HlyA signal, which may indicate something inherent in this protein
that makes it easiest to secrete in one step (Type I secretion). TolB was the least
successful signal tested, with the majority of proteins neither expressed nor secreted.
Future Directions
Realistically, as new effector genes are discovered or created, a case-by-case
empirical testing to obtain a functional and secretable effector product will be needed.
This study shows that there is no predicted response for how a secretion signal or effector
protein will behave in P. agglomerans, let alone the most-studied bacterium in the world,
E. coli. It is just as probable that an effector protein would require no modifiers as it
would need a unique series of modifiers in order to see it expressed and/or secreted from
the cell.
Luckily, there are methods that are continually being developed for improving the
yield and activity of a secreted protein. With the co-expression of chaperone proteins
that act in the cytoplasm or periplasm to aid in folding and processing of nascent
polypeptides, the yield of soluble and secreted protein could increase dramatically
(KOLAJ et al. 2009). These chaperone proteins could first be provided on helper plasmids
to see if their presence improves production and secretion.
Because there are concerns regarding paratransgenic bacterium carrying multiple
plasmids in the wild, there are ways to limit the amount of extraneous DNA carried by
the bacterium. As a first test, the chaperone protein genes and effector protein genes
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could be combined on one plasmid, possibly under control of the same promoter
(HAYHURST and HARRIS 1999). Organizing these genes in an operon would ensure
simultaneous production of the effector protein and the chaperones that it needs (Figure
3.6). Secondly, this operon could be cloned into a transposable element that would
incorporate into the chromosome. As long as a single-copy version of this operon
showed promise as an effective means of Plasmodium inhibition, this would reduce the
already rare chance of horizontal gene transfer. This organization may also improve the
expression of some of the effector proteins that may be too toxic to the cell if they are
translated from a multicopy plasmid.
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TABLE 3.1: N-terminal Secretion Signal Sequences
Signal
PelB
OmpA
TolB

Sequencea
MKYLLPTAAAGLLLLAAQPAMA⇓EV…
MKKTAIAIAVALAGFATVAQA⇓MAEV…
MKQALRVAFGFLILWASVLHA⇓AQPAMAEV…

Reference
(WINTER et al. 1994)
(THIE et al. 2008)
(THIE et al. 2008)

The ⇓ indicates the predicted cleavage site. The residues in italics represent the amino terminus of a
secreted protein. Additional amino acids not belonging to the signal sequence are underlined.

a
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TABLE 3.2 Strains Used in This Study
Strain
E. coli Top10

E. coli Top10 F’
S. cerevisiae INVSc-1
E. coli BW25113

Relevant characteristicsa
F mcrA Δ(mrr-hsdRMS-mcrBC) ø80lacZΔM15
ΔlacX74 recA1 araD139 Δ (ara-leu)7697 galU galK
rpsL (StrR) endA1 nupG
Top 10 with F’[lacIq Tn10 (TcR)]
Sc1: MATa his3D1 leu2 trp1-289 ura3-52
MATα his3D1 leu2 trp1-289 ura3-52
lacIq rrnB ΔlacZ hsdR514 ΔaraBAD ΔrhaBAD
-

E. coli ET12567

Source or Reference
Invitrogen Corporation

Invitrogen Corporation
Invitrogen Corporation
(DATSENKO and
WANNER 2000)
(MACNEIL et al. 1992)

dam-13::Tn9 dcm-6 hsdM hsdR recF143
zjj201::Tn10 galK2 galT22 ara-14 lacY1 xyl-5 leuB6
thi-1 tonA31 rpsL136 hisG4 tsx-78 mtl-1 glnV44 FE. coli LL308
(ZENGEL et al. 1980)
Δ(pro-lac) recA nalA supE thi/F’ pro+lacIq
lacZΔM15
(WINTER et al. 1994)
E. coli HB2151
Δlac-pro ara nalA thi F’ (proAB lacIq lacZΔM15)
P. agglomerans
Wild-type strain isolated from Johns Hopkins U.
(RIEHLE et al. 2007)
mosquitoes
P. agglomerans E325
Commercial strain isolated from plant matter; RifR
(PUSEY 2002)
a
R
Str , streptomycin resistance; TcR, tetracycline resistance; NalR, nalidixic acid resistance; RifR, rifampicin
resistance
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TABLE 3.3 Plasmids Used in This Study
Plasmid
pIJ790
pIJ799
pUZ8002
pMQ64
pDB27
pHA-2-5-1
pDL200.3
pTOPO-PLA2-H67N
pAgCP-CEL-III
PelB
pIT2-scFv
pDB36
pDB48
pDB51
pDB52
pDB53
pDB54
OmpA
pDB67
pDB69
pDB71
pDB72
pDB73
TolB
pDB68
pDB70
pDB75
pDB76
pDB77
HlyA
pVDL9.3
pEHLYA2-SD
pDB47
pDB49
pDB50
pDB58
pDB59
pDB60

Relevant Characteristicsa
CamR; λ Red (gam, bet, exo) araC rep101ts
AprR; source of aac(3)IV-oriT cassette with bla homology
KanR; RK2 derivative, nontransmissible plasmid in E. coli
GentR; yeast recombination vector containing colE1 ori
CamR; source of malE-anti BSA scFv
source of SM1 effector gene (encodes 2 tandem copies)
source of Anti-Pbs21 effector gene
source of PLA2-H67N effector gene
source of CEL-III effector gene

Source or Reference
(GUST et al. 2004)
(GUST et al. 2004)
(PAGET et al. 1999)
(SHANKS et al. 2006)
Bisi, D.C., unpublished
(GHOSH et al. 2001)
Lampe, D.J., unpublished
(MOREIRA et al. 2002b)
(YOSHIDA et al. 2007)

ApR; pIT2 with α-BSA scFv between pelB and epitope tags
AprR; pIT2-scFv with bla gene replaced with aac(3)IV
GentR; pelB-AscI-6His-myc-STOP cloned in pMQ64 MCS
GentR; pDB48/Anti-BSA scFv
GentR; pDB48/2-SM1
GentR; pDB48/Pbs21
GentR; pDB48/PLA2-H67N

(WINTER et al. 1994)
This study
This study
This study
This study
This study
This study

GentR; ompA-AscI-6His-myc-STOP cloned in pMQ64 MCS
GentR; pDB67/α-BSA scFv
GentR; pDB67/2-SM1
GentR; pDB67/Pbs21
GentR; pDB67/PLA2 H67N

This study
This study
This study
This study
This study

GentR; tolB-AscI-6His-myc-STOP cloned in pMQ64 MCS
GentR; pDB68/α-BSA scFv
GentR; pDB68/2-SM1
GentR; pDB68/Pbs21
GentR; pDB68/PLA2 H67N

This study
This study
This study
This study
This study

CamR; production of HlyB and HlyD transporters
ApR; polylinker for cloning ORFs in frame with E-tagged
‘hlyA (23-kDa C-terminal domain of HlyA)
AprR; pEHLYA2-SD with bla gene replaced with aac(3)IV
AprR; pDB47/ α-BSA scFv
AprR; pDB47malE-α-BSA scFv
AprR; pDB47/SM1
AprR; pDB47/Pbs21
AprR; pDB47/PLA2-H67N

(TZSCHASCHEL et al. 1996)
(FERNANDEZ et al. 2000)

a

This study
This study
This study
This study
This study
This study

ApR, ampicillin resistance; AprR, apramycin resistance; CamR, chloramphenicol resistance; GentR,
gentamycin resistance; MCS, multiple cloning site
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Figure 3.1: Secretion constructs used in this study. The Type II secretion-based
construct (PelB, OmpA, and TolB) is shown in Figure 3.1A. The lac promoter drives
expression of the effector gene, which was tagged with an N-terminal secretion signal
(T2SS) and C-terminal epitope tags (6His myc). The plasmid carries the colE1 origin of
replication and the aac(3)IV gene (apramycin resistance). Figure 3.1B shows the
hemolysin (‘hlyA) secretion-based construct. Again, the lac promoter drives expression
of the effector gene, which is tagged at its C-terminal end with the 6His and myc epitopes
(Tags), as well as the E-tag (E). The effector is fused to the 3’ end of hemolysin A
(‘hlyA). The hemolysin construct must be co-expressed with pVDL9.3, which provides
the membrane channel proteins HlyB and HlyD. (RBS = ribosome binding site)
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Figure 3.2: Secretion of proteins using PelB in E. coli and P. agglomerans. Figure 3.2A
shows an ELISA analysis of overnight supernatants from E. coli, P. agglomerans, and the
commercial P. agglomerans strain E325 expressing pDB36 (pelB-anti-BSA scFv). The
negative controls are P. agglomerans and Eh325 with no plasmid (N.C.). Figure 3.2B
compares the averaged signal from the BSA-coated wells for each strain. Figure 3.2C shows
the presence or absence of various proteins in the cell pellet (P) or spent growth medium
supernatant (S) collected from overnight cultures of E. coli and P. agglomerans. The antiBSA scFv antibody is secreted in both species. The anti-Plasmodium effector SM1 is
expressed in both species both not secreted, and Anti-Pbs21 is expressed and secreted in
E. coli only. P. agglomerans without a plasmid served as a negative control for the Western
blot analysis (N.C.). The proteins were detected using a α-myc antibody.
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Figure 3.3: Secretion of proteins using OmpA in E. coli and P. agglomerans. Figure
3.3A shows an ELISA analysis of overnight supernatants from E. coli and P. agglomerans
carrying pDB69 (ompA-anti-BSA scFv). The proteins were not active in either species.
The positive control is HB2151 transformed with pDB36 and a negative control is
P. agglomerans with no plasmid (N.C.). The averaged signal from the BSA-coated wells for
each strain is shown in Figure 3.3B. Figure 3.3C shows the presence or absence of various
proteins in the cell pellet (P) or spent growth medium supernatant (S) collected from
overnight cultures of E. coli and P. agglomerans. The anti-BSA scFv antibody is expressed
and secreted only in E. coli. The anti-Plasmodium effector Anti-Pbs21 was expressed and
secreted by E. coli, and PLA2 H67N were expressed, but not secreted, by both species.
P. agglomerans with no plasmid is the negative control for Western analysis (N.C.).
The proteins were detected using a α-myc antibody.
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Figure 3.4: Secretion of proteins using TolB in E. coli and P. agglomerans. Figure 3.4A
shows an ELISA analysis of overnight supernatants from E. coli and P. agglomerans
carrying pDB70 (tolB-anti-BSA scFv). The proteins were not active in either species.
The positive control is HB2151 transformed with pDB36 and a negative control is
P. agglomerans with no plasmid (N.C.). Figure 3.4B shows the averaged signal from the
BSA-coated wells for each strain. Figure 3.4C shows the presence or absence of various
proteins in the cell pellet (P) or spent growth medium supernatant (S) collected from
overnight cultures of E. coli and P. agglomerans. The anti-BSA scFv antibody is expressed,
but not secreted in E. coli. None of the anti-Plasmodium effectors tested (SM1, Anti-Pbs21,
or PLA2 H67N) were expressed or secreted in either species. P. agglomerans with no
plasmid is the negative control for Western analysis (N.C.). The proteins were detected
using a α-myc antibody.

107

Figure 3.5: Secretion of proteins using HlyA in E. coli and P. agglomerans. Figure 3.5A
shows an ELISA analysis of overnight supernatants from E. coli and P. agglomerans
carrying pDB49 (Anti-BSA scFv-‘hlyA) or pDB50 (malE-Anti-BSA scFv-‘hlyA). The
proteins were not active in either species. The positive control is HB2151 transformed with
pDB36 and a negative control is P. agglomerans with no plasmid (N.C.). The averaged
signal from the BSA-coated wells for each strain is shown in Figure 3.5B. Figure 3.5C
shows the presence or absence of various proteins in the cell pellet (P) or spent growth
medium supernatant (S) collected from overnight cultures of E. coli and P. agglomerans.
The Anti-BSA scFv antibody is secreted in both species, but the MalE-Anti-BSA scFv fusion
is only expressed in E. coli. The anti-Plasmodium effectors Anti-Pbs21 and PLA2 H67N
were secreted as HlyA fusions by both species. P. agglomerans with no plasmid is the
negative control for Western analysis (N.C.). The proteins were detected using a α-myc
antibody.
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TABLE 3.4: Summary of Expression and Secretion Results Using all Signals and Effector
Proteins in E. coli and P. agglomerans

E. coli
P. agg
E. coli
P. agg
E. coli
P. agg
E. coli
P. agg

Protein
Anti-BSA
SM1
Pbs21
PLA2-H67N

PelB
HlyA
Exp.a Secr.b Exp.
Y
Y
Y
Y
Y
Y
Y
N
N
Y
N
N
Y
Y
Y
N
N
Y
N
N
Y
N
N
Y

a

Secr.
Y
Y
N
N
Y
Y
Y
Y

OmpA
Exp.
Y
N
N
N
Y
N
Y
Y

Secr.
Y
N
N
N
Y
N
N
N

TolB
Exp.
Y
N
N
N
N
N
N
N

Expression of the protein as visualized by Western Blot; b Secretion of the protein as visualized by
Western Blot
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Secr.
N
N
N
N
N
N
N
N

Figure 3.6: Proposed polycistronic effector and chaperone construct. This figure
presents a hypothetical operon for expression of a secreted effector protein and its necessary
chaperones for optimal secretion and activity. The lac promoter would drive expression of
the effector gene as well as the chaperones dsbA, dsbC, fkpA, and surA (SCHLAPSCHY et al.
2006). The proteins would all be translated at the same time, thus increasing the likelihood
of the chaperone proteins interacting with the effector protein and optimizing its potential for
secretion and inhibition of Plasmodium.

110

CHAPTER 4
SUMMARY AND FUTURE DIRECTIONS
The research presented in this dissertation is part of a paratransgenic approach to
combating the spread of malaria. Malaria is caused by the protist Plasmodium and is
vectored to humans by female anopheline mosquitoes. A bacterial symbiont of the mosquito
gut environment, Pantoea agglomerans, is a candidate for expression and delivery of antiPlasmodium effector products. An important caveat of this approach is that the effector
product must be secreted from the bacterial cell in order to be effective against Plasmodium.
This research focused on characterizing and utilizing secretion signals for use in this
bacterium.
P. agglomerans was tested, along with the more-characterized species E. coli, for the
expression and secretion of various anti-Plasmodium effector products using several protein
secretion signals. These included a native P. agglomerans signal within the FliC/Flagellin
protein that was characterized after a search for native secreted proteins was performed using
spent growth medium. Also, a collection of secretion signals (PelB from Erwinia
carotovora; OmpA, TolB, and HlyA from E. coli) was assessed for their ability to mediate
secretion in P. agglomerans. The FliC/Flagellin sequences did not work as a secretion signal
in P. agglomerans. And ultimately, there was no predictable pattern of success when pairing
a secretion signal with an effector gene. The results were mixed within each signal used, each
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effector gene tested, and even within the behavior of E. coli or P. agglomerans expressing a
particular construct. However, P. agglomerans was able to secrete the effectors Anti-Pbs21
and PLA2 H67N as fusions to the HlyA C-terminal secretion signal, and these strains have
been sent to Johns Hopkins University. Trials are currently underway there to determine the
efficacy of these strains in inhibiting Plasmodium development in Plasmodium-infected
mosquitoes.
Native Secretion Signals
Chapter two summarizes the search for native P. agglomerans secreted proteins and their
corresponding genes. It was hypothesized that the secretion signal within these genes could
be used for secretion of a passenger anti-Plasmodium protein. Most signals used for
secretion of heterologous proteins come from well-characterized proteins in E. coli, and it
was expected that a secreted protein from a bacterium like P. agglomerans (an environmental
isolate with no completed genome sequence) may not behave in the same fashion or perform
at all.
The native secreted protein search did not provide a great variety of secreted proteins.
Despite the detection of 16 secreted proteins by 2D-PAGE, only 10 could be identified based
on sequence homology to protein sequences in the NCBI Enterobacteriaceae database.
Within these 10, three pairs of spots matched to the same protein, indicating that isoforms of
one protein were being treated as unique proteins. Moreover, most identities matched to
putative intracellular proteins with vague descriptors like “hydrogenase” or “periplasmic
protein” (Table 2.4). Finally, one protein, FliC/Flagellin, was identified as a bona fide
secreted protein (ALDRIDGE and HUGHES 2001; CHEVANCE and HUGHES 2008; MINAMINO
and NAMBA 2004). Previously published data shows FliC/Flagellin functions as a signal for
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recombinant protein secretion in E. coli and Salmonella typhimurium (MAJANDER et al. 2005;
VEGH et al. 2006; YOUNG et al. 1999).
The P. agglomerans fliC 5’UTR and fliC ORF were tested for their ability to mediate
secretion of an anti-BSA scFv in P. agglomerans cells that still had the intact fliC gene.
There was a complete inability to detect expression of the test protein in the pellet, as well as
secretion into the growth medium. The fliC gene was abandoned as a secretion signal for
mediating heterologous secretion.
As the sequencing of bacterial genomes and proteomes becomes more routine, and
databases are updated, the results generated in this study can be re-evaluated. The identity of
the remaining unknown proteins (Figure 2.1 and Table 2.4) may be revealed after a search
through a more current database. Also, the treatment performed at the Taplin facility,
namely trypsin digestion followed by LC-MS/MS (liquid chromatography-tandem-massspectrometry), which generates mass fingerprinting and provides users with tryptic peptide
masses in a mass spectrum that can be matched to calculated tryptic peptide masses in a
database, is sometimes not enough to identify an unknown protein (STEEN and MANN 2004).
Using alternate peptide sequencing techniques like de novo peptide sequencing may also
identify more secreted proteins for testing in secretion trials.
De novo peptide sequencing takes the mass spectrometry output data and uses that to
directly determine the primary amino-acid sequence, and the success of identification
depends greatly on the quality of data. However, experts warn that the mass accuracy and
resolution of the instrument can skew interpretations (STEEN and MANN 2004).
In summary, a native secretion protein from a species like P. agglomerans may never
work as a signal for recombinant protein production. Additional secreted proteins could be
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identified and tested as with fliC, however, it may be more time-saving and successful to
optimize a heterologous secretion signal for use in this species (Chapter 3).
Heterologous Secretion Signals
Four secretion signals, known to work in E. coli, were tested in E. coli and
P. agglomerans for secretion of four different proteins (Anti-BSA scFv, and the antiPlasmodium effectors SM1, Anti-Pbs21 scFv, and PLA2 H67N). PelB and OmpA are Nterminal signal sequences that result in Type II-mediated secretion. TolB is a signal used by
the bacterial SRP secretion pathway. When the C-terminus of HlyA is fused to a passenger
protein, it is exported from the cell in a Type I secretion pathway. The results from Chapter
3 reveal no clear pattern of successful secretion with one signal or effector protein. It is
unpredictable whether the pairing of a signal and effector protein will result in a functional,
secreted protein. Fortunately, there are additional tools to test in conjunction with the
secretion constructs made in this study that could aid in secretion and restore function and/or
folding of the effector protein.
It may be that asking an environmental isolate like P. agglomerans to express and secrete
heterologous proteins is too tall an order. The data presented in Chapter 3 shows that it often
is too much to ask even of a long-domesticated laboratory strain like E. coli! It may be
possible to take advantage of the considerable efforts by the biotechnology industry to devise
ways to improve secretion. For example, the co-expression of a number of folding and/or
protein modifying chaperones can greatly improve the yield, solubility, or activity of the
desired protein product (KOLAJ et al. 2009). One major difficulty is that improvement cannot
be predicted and it takes time to determine the correct “cocktail” of chaperones needed for a
particular recombinant protein.
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As a starting point, the Lampe laboratory has received a helper plasmid called pTUM4
that encodes four periplasmic molecular chaperones, DsbA, DsbC, FkpA, and SurA
(SCHLAPSCHY et al. 2006). The chloramphenicol resistance gene is compatible with
P. agglomerans. The co-expression of pTUM4 with each of the anti-Plasmodium effector
constructs (Table 3.2) should be tested. Perhaps these chaperones will aid in the periplasmic
folding (disulfide bond formation and cis/trans isomerization) of the effector proteins and
they will be more efficiently processed and secreted. In addition to the proteins provided on
pTUM4, there are several other chaperones that could improve expression or secretion for
each particular signal/effector protein pair, and these are presented in the discussion section
of Chapter 3.
If a “magic bullet” is found that improves secretion and processing of an effector protein,
it would be most efficient to organize the corresponding gene(s) along with the secretion
signal and effector gene in a polycistronic operon (Figure 3.6). If one promoter drove
expression of the secretable effector gene and corresponding chaperones, this would greatly
ensure the co-production of these proteins and enhance the chaperone’s availability to the
effector protein directly upon translation.
What is most important to note is that P. agglomerans is capable of secreting an active
single-chain antibody (the anti-BSA scFv) using the PelB signal (Figure 3.2). This is an
important finding because, in principle, the anti-BSA scFv in the pDB36 construct can be
replaced with anti-Plasmodium scFvs and tested for secretion and activity against
Plasmodium parasites present in infected mosquito guts.
It is encouraging that P. agglomerans is able to secrete an active scFv via the pDB36
construct, because there are several anti-Plasmodium mouse monoclonal antibodies known to
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block Plasmodium transmission that can be converted to scFv form and tested in pDB36 and
the other secretion constructs made in this study (BARR et al. 1991; LI et al. 2005; QUAKYI et
al. 1987; RENER et al. 1983). Pfs25 is expressed on the surface of zygote and ookinete forms
of P. falciparum and monoclonal antibodies against this antigen have resulted in the
complete failure of the parasite to transition to the oocyst stage inside the mosquito gut
(BARR et al. 1991). The Pfs48/45 antigens are found on the surface of P. falciparum
gametocytes and monoclonal antibodies have reduced the infectivity of this parasitic stage by
preventing fertilization of gametes taken up during a blood meal (RENER et al. 1983). The
Pfs230 monoclonal antibody is also active against gametocyte and zygote stages of P.
falciparum and interferes with the infectivity of the parasite (QUAKYI et al. 1987). Finally,
an anti-chitinase monoclonal antibody (PfCHT1) has already been converted to an scFv form
and been shown to reduce the transmission of P. falciparum and P. gallinaceum (avian
malarial parasite) to mosquitoes (LI et al. 2005). The three Pfs antibodies can be converted
to scFv using standard procedures and primers designed for mouse Vl, Vk, and VH genes
(TOLEIKIS et al. 2004).
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APPENDIX 1
Isolation of Secondary Secreted Protein Candidates:
P. agglomerans flgL and ssb
Objective and Summary
In order for a paratransgenic strain of P. agglomerans to effectively target
Plasmodium development in the mosquito gut, the effector proteins that it expresses must
be secreted from the bacterial cell. To this end, a search for native secreted proteins was
performed using spent growth medium, 2D-PAGE resolution of the proteins present, and
MALDI-TOF analysis to identify the proteins. The primary secreted protein candidate
found in this search was FliC/Flagellin and information regarding the isolation of the fliC
gene and its utilization are found in Chapter 2. Among the remaining proteins identified
were FlgL (flagellar hook-associated protein 3) and Ssb (single-stranded DNA-binding
protein). Experimental steps similar to those in Chapter 2 were taken to isolate the genes
for these secondary secreted protein candidates. These steps involved genome walking
PCR using degenerate primers designed from the peptide fragments identified with
MALDI-TOF. In the case of flgL, the gene that was isolated was believed to be E. coli
contamination because the sequence similarity to E. coli flgL was 99.7%. This
contamination must have arisen at some point in the preparation of the genomic DNA
template. As a result, the flgL gene that was isolated was not used for the creation of any
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secretion constructs. The P. agglomerans ssb gene was successfully isolated and
sequenced, and as a result, two secretion constructs were made using the ssb ORF.
Ultimately, it is doubtful that Ssb is a true secreted protein as it is mainly involved in
intracellular DNA processes. Ssb most likely appeared in the secreted protein profile due
to cell lysis during growth of the culture or collection of the cells prior to protein
precipitation.
Materials and Methods
MALDI-TOF analysis. This analysis is explained in Ch. 2 Materials and Methods.
Genome Walking PCR. This PCR technique is explained in Ch. 2 Materials and
Methods.
Plasmid construction. The plasmids in this study were constructed using the yeast gap
repair method as previously described by Shanks et al (SHANKS et al. 2006). Briefly, the
vector to be modified was digested with restriction enzymes and treated with a
phosphatase. DNA inserts were amplified with oligos that contained 40 bp of homology
to the digested vector (up to 2000 bases from the digestion site). Agarose gel-purified
vector (~20-200 ng) and inserts (50-500 ng), along with herring sperm DNA (100 μg)
were co-transformed into 8-10 colonies of S. cerevisiae INVSc-1 cells (Invitrogen)
resuspended in 500 μl of PLATE solution (50% PEG, 100 mM LiAc, 10 mM Tris, pH
7.4, 1 mM EDTA). The cells were incubated on the benchtop for ~2 d. After heat shock
at 42°C for 30 min, the yeast cells were resuspended in 150 μl of deionized H2O and
plated on uracil drop-out medium (6.7 g/L yeast nitrogen base minus amino acids, 1.92
g/L yeast synthetic drop-out media supplement without uracil, 2% glucose (w/v) and 20
g/L bacteriological agar) and incubated at 30°C for up to 2 d. Total yeast DNA was
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purified from the colonies using the “Yeast Smash and Grab DNA Miniprep” protocol
(ROSE et al. 1990). Fifty nanograms of total yeast DNA was transformed into an
appropriate strain of E. coli and bacterial clones were verified for the resultant plasmid by
restriction enzyme digestion and DNA sequencing.
The yeast-replicating vector, pDB14, was built as follows. pACYC184 (New
England Biolabs) was digested with XmnI for 1.5 h followed by treatment with calf
intestinal phosphatase for 1 h at 37°C. The 2 μm ori and URA3 gene from the yeast
cloning vector pMQ64 were amplified as a single PCR product with 40 bp of homology
to pACYC184 and recombined into the XmnI cut site.
pDB24 was made by digesting pDB14 with HindIII-EagI and recombining in the
P. agglomerans fliC 5’UTR (amplified from the P. agglomerans chromosome) with an
AscI site at the 3’ end, and the 6His and myc epitope sequences and stop codon from
pIT2-scFv. Then, pDB27 was constructed by digesting pDB24 with AscI and
recombining in the malE gene from pMALTM-c2X and scFv gene from pIT2-scFv (see
Table A1.2). pDB27 allows for the expression of the fusion protein MalE-Anti-BSA
scFv under the control of the P. agglomerans fliC promoter. Finally, the fliC 5’UTR in
pDB27 was replaced by digesting the vector with EcoNI and recombining the Ptac
promoter from pMALTM-cRI to make pDB28.
To make pDB29, pDB28 was digested with BglI and the P. agglomerans ssb ORF
(amplified from the P. agglomerans chromosome) was recombined in frame behind the
anti-BSA scFv ORF by yeast recombination. To make pDB31, pDB27 was digested with
EcoNI and the P. agglomerans ssb ORF was recombined in frame after the Ptac promoter
and before the malE ORF using yeast recombination.
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Results
Isolating flgL and ssb based on peptide sequence.
The flgL and ssb genes were isolated from the P. agglomerans chromosome using
a genome walking PCR technique (GUO and XIONG 2006). Figure A1.5 and A1.6 show
the P. agglomerans FlgL and Ssb peptide fragments that were identified and their relative
placement in the E. coli flgL and ssb sequences (shown in green), as well as the site of
degenerate PCR primer design (red arrows). The primers were based on Gram-negative
codon usage tables and allowed for as much degeneracy as possible to ensure a successful
amplification of the corresponding DNA sequence (SAMBROOK and RUSSELL 2001). The
sequence of these primers and the series of universal “walking primers” are given in
Table A1.3. PCR products ranging in size from 200-600 bp were cloned using TOPO
technology (Invitrogen Corporation). The DNA sequence from these PCR products was
used to generate a P. agglomerans flgL or ssb contig from which additional specific
primers could be designed and sequential rounds of genome walking PCR could be
performed. This procedure was repeated until the entire P. agglomerans gene and the
flanking DNA up to and including some of the neighboring genes was isolated and
sequenced (Figures A1.5 and A1.6).
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TABLE A1.1 Strains Used in This Study
Relevant characteristicsa
Source or Reference
Invitrogen Corporation
F mcrA Δ(mrr-hsdRMS-mcrBC) ø80lacZΔM15
ΔlacX74 recA1 araΔ139 D(ara-leu)7697 galU galK
rpsL (StrR) endA1 nupG
E. coli Top10 F’
Top 10 with F’[lacIq Tn10 (TcR)]
Invitrogen Corporation
S. cerevisiae
Sc1: MATa his3D1 leu2 trp1-289 ura3-52
Invitrogen Corporation
INVSc-1
MATα his3D1 leu2 trp1-289 ura3-52
a
StrR, streptomycin resistance; TcR, tetracycline resistance; NalR, nalidixic acid resistance
Strain
E. coli Top10

-

TABLE A1.2 Plasmids Used in This Study
Relevant Characteristicsa
Source or Reference
Cam , Tc ; cloning vector with p15A low copy ori
(CHANG and COHEN 1978)
GentR; yeast recombination vector and source of yeast
(SHANKS et al. 2006)
ori (2μm) and yeast URA3 gene
New England Biolabs
pMALTM-c2X ApR; source of malE (maltose binding protein) gene
pMALTM-cRI
ApR; source of Ptac
New England Biolabs
pIT2-scFv
ApR; source of anti BSA scFv gene with 6His and myc
(DE WILDT et al. 2000)
epitopes
pDB14
This study
CamR; pACYC184/2μm ori and URA3 gene
This study
pDB24
CamR; pDB14/P. agg fliC 5’UTR-AscI-6His-mycSTOP
pDB27
CamR; pDB24/P. agg fliC 5’UTR-malE-anti BSA scFv This study
pDB28
CamR; pDB14/Ptac-malE-anti-BSA scFv
This study
pDB29
CamR; pDB28/Ptac-malE-anti-BSA scFv-ssb
This study
pDB31
CamR; pDB27/ Ptac-ssb-malE-anti BSA scFv
This study
a
R
Ap , ampicillin resistance; CamR, chloramphenicol resistance; GentR, gentamycin resistance; TcR,
tetracycline resistance
Plasmid
pACYC184
pMQ64

R

R
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Table A1.3: Oligonucleotides used in this Study
Oligonucleotide
M13 Forward (-20)
M13 Reverse
Semi-1
Semi-2
Semi-3
Semi-4
FlgL134-140 For
FlgL203-212 Rev1
FlgL236-247 Rev2
flgL-nest1-Left

Sequence 5’- 3’a
GTAAAACGACGGCCAG
CAGGAAACAGCTATGAC
GCCAATTCCGGATNGAYKSNGGNTC
GCCTTAAGGCCTANGARMSNCCNAG
CGGTTAAGGCCTANYTCSKNGANGC
GCCAATTCCGGATNSAGYMNCTNCG
TAYATYTTYGCNGGNTAYAAR
NGTYTTNARNGCNGCRATNGC
NACNGTNARNACRTTRTTNA
ATGCGCWTWAGYACTMRMATGATG

Purpose
Sequencing TOPO inserts
Sequencing TOPO inserts
Arbitrary walking primer
Arbitrary walking primer
Arbitrary walking primer
Arbitrary walking primer
Genome Walking PCR
Genome Walking PCR
Genome Walking PCR
Nested Genome Walking
PCR
flgL-nest2-Left
TACCAGCAAAAYATGCRWGGGARYAYT G
Nested Genome Walking
PCR
flgL-nest1-Right
CTGGAAMAGMGACATTCCCTGC
Nested Genome Walking
PCR
flgL-nest2-Right
ATCGCTRAAYGCTTTATASGAWGCSTG
Nested Genome Walking
PCR
flgL check Left
AATGGCACCTTGAGTGACGATG
Verify P. agg flgL gene
flgL check Right
GTGCAATGCCGTTTGCTGCATG
Verify P. agg flgL gene
Ssb5-22 For
GGNGTNAAYAARGTNATYYTNG
Genome Walking PCR
Ssb74-85 Rev1
YTGNCCYTCRATRTANACYTG
Genome Walking PCR
Ssb98-116 Rev2
CATYTGCATNGTNCCNCCNACRTTNAC
Genome Walking PCR
ssb-nest1-Left
ATGGCCAGCAGAGGCGTWAAYAARG
Nested Genome Walking
PCR
ssb-nest2-Left
ATTCTYGTYGGKAATCTGGGYCARG
Nested Genome Walking
PCR
ssb-nest1-Right
GAAMGGAATRTCGTCRTCRAARTCCATYGG Nested Genome Walking
PCR
ssb-nest2-Right
CATYGGSGGYTCGTTAGACGG
Nested Genome Walking
PCR
a
R = A or G; Y = C or T; N = any nucleotide; K = G or T; M = A or C; S = G or C; P. agg, P. agglomerans
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Figure A1.1 FlgL MALDI-TOF Results from Taplin Biological Mass Spec Facility.
Results from MALDI-TOF analysis of each individual spot are viewed by signing in to
the Taplin Biological Mass Spec Facility website with a provided username and
password. In the lower left-hand corner is a menu of protein matches that shows the
number of peptide fragments isolated for this particular spot (5 total). Each ID number
takes the user to a screen that shows where each of the peptide fragments align to a
known protein in the NCBI Enterobacteriaceae database. In this case, the peptide
fragments matched to E. coli FlgL.
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Figure A1.2: Peptide fragment matches to E. coli FlgL from Taplin Biological Mass
Spec Facility. In the case of the spot that matched to E. coli FlgL, five peptide fragments
were generated upon tryptic digestion. This screenshot shows where 4 of the 5 fragments
matched to the E. coli FlgL protein sequence present in the NCBI Enterobacteriaceae
protein database (2 fragments are overlapping). The amino acid positions are given as
well as the amino acid sequence of the fragment.
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Figure A1.3: Ssb MALDI-TOF Results from Taplin Biological Mass Spec Facility.
Results from MALDI-TOF analysis of each individual spot are viewed by signing in to
the Taplin Biological Mass Spec Facility website with a provided username and
password. In the lower left-hand corner is a menu of protein matches that shows the
number of peptide fragments isolated for this particular spot (4 total). Each ID number
takes the user to a screen that shows where each of the peptide fragments align to a
known protein in the NCBI Enterobacteriaceae database. In this case, the peptide
fragments matched to E. coli Ssb.
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Figure A1.4: Peptide fragment matches to E. coli Ssb from Taplin Biological Mass
Spec Facility. In the case of the spot that matched to E. coli Ssb, four peptide fragments
were generated upon tryptic digestion. This screenshot shows where the four fragments
(2 were overlapping) matched to the E. coli Ssb protein sequence present in the NCBI
Enterobacteriaceae protein database. The amino acid positions are given as well as the
amino acid sequence of the fragment.

137

A.
1
61
121
181
241
301

mrfstqmmyq
qytlartfat
llnlanttdg
dsitsnavae
nnvltvrael
ykaftdmqgl

qnmrgitnsq
qkvsleesvl
ngr yifagyk
pdgsasetnl
gtqlnelesl
slfqlsk

aewmkygeqm
sqvttaiqna
tetapfseek
fa mldsaiaa
dslgsdralg

stgkrvvnps ddpiaasqav vlsqaqaqns
qekivyasng tlsdddrasl atdiqglrdq
gkyvggaesi kqqvdasrsm vightgdkif
lktpvadsea dketaaaald ktnrg lknsl
qtqqmsdlvd vdwnatissy imqqtalqas

B.
flgK

flgL

RNase E
~1.5 kb

Figure A1.5: Identity and placement of sequenced P. agglomerans FlgL peptide
fragments in the E. coli FlgL sequence and the P. agglomerans flgL contig assembled
after genome walking PCR. Five P. agglomerans FlgL peptide fragments were
sequenced using MALDI-TOF and identified based on homology to the E. coli FlgL
sequence. A1.5A shows where the fragments (2 fragments are overlapping) match to the
E. coli FlgL sequence (residues in green). The red arrows indicate where the degenerate
primers were designed (Table A1.3). A1.5B shows the resulting P. agglomerans flgL
contig assembled after genome walking PCR. The blue bracket roughly indicates the
length of sequence obtained.

138
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Figure A1.6: Identity and placement of sequenced P. agglomerans Ssb peptide
fragments in the E. coli Ssb sequence and the P. agglomerans ssb contig assembled
after genome walking PCR. Four P. agglomerans Ssb peptide fragments were
sequenced using MALDI-TOF and identified based on homology to the E. coli Ssb
sequence. A1.6A shows where the fragments (2 fragments are overlapping) match to the
E. coli Ssb sequence (residues in green). The red arrows indicate where the degenerate
primers were designed (Table A1.3). A1.6B shows the resulting P. agglomerans ssb
contig assembled after genome walking PCR. The blue bracket roughly indicates the
length of sequence obtained. Because a downstream ORF was not found, it is likely
additional “walking” is needed in order to find the next gene.
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Figure A1.7: Secretion constructs using P. agglomerans ssb ORF. Two constructs
were made using the P. agglomerans ssb ORF as the secretion signal for export of the
MalE-anti-BSA scFv fusion protein (malE-scFv).

These plasmids were made using

yeast recombination. When expressed, the Ssb protein is fused to the C-terminal end of
the passenger protein in pDB29, and also fused to the N-terminal end of the passenger
protein in pDB31. The Ptac promoter is driving the expression of the genes. The coding
sequence for these proteins contains the 6His and myc epitope tags (“TAGS”).
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APPENDIX 2
Growth Curve of Wild-type P. agglomerans
Objective and Summary
A growth curve of wild-type P. agglomerans cells grown in Luria-Bertani (LB)
broth was constructed. The objective was to collect spent medium for 2D-PAGE during
late-log phase, which would allow for the highest concentration of secreted protein and
the lowest concentration of lysed cells in the culture.
A 5 ml overnight culture of P. agglomerans in LB broth was grown at 30°C in a
shaking incubator set to 250 rpm. On the next day, a 20 ml LB culture was established
using a 1/100 dilution of the overnight culture. Incubation continued at 30°C in the
shaking incubator and a 1 ml aliquot was removed every hour for an OD600 reading in a
Perkin Elmer MBA 2000 spectrophotometer. Deionized water was used as a blank.
After four hours, a 1/10 dilution of the 1 ml aliquot of the culture was used to obtain a
reading that was still within range of the spectrophotometer.
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Figure A2.1: Growth curve of Wild-type P. agglomerans in LB Broth. This graph
shows the logarithmic growth of wild-type P. agglomerans cells in LB broth. Samples
were collected every hour for a total of 8 hours and the OD600 reading was plotted on the
y-axis.

142

APPENDIX 3
Parallel 2D-PAGE preparations for MALDI-TOF
analysis of secreted P. agglomerans proteins
Objective and Summary
The Taplin Biological Mass Spec Facility at Harvard Medical School encourages
researchers submitting samples for MALDI-TOF analysis to only send samples that are
detectable at the Coomassie stain level. Because the majority of spots on the 2D-PAGE
gels of secreted P. agglomerans proteins were detectable with the more sensitive reagent
silver stain, in order to increase the amount of protein per spot, parallel gels were run and
identical spots were cored from the gel and combined in a single tube prior to sending to
the facility. The gel shown in Figure 2.1 and the six gels shown here in Appendix 3
(Figures A3.1 and A3.2) represent the source of all of the spots sent for identification at
the Taplin Facility. The spots (labeled A-O) were chosen for identification based on
reproducibility of the same spot from gel to gel and the relative intensity compared to
more faint spots on the gels.
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Figure A3.1: Parallel gels of late-log protein preparations of P. agglomerans
secreted proteins. In order to increase the amount of protein per sample (spot) sent for
identification, parallel 2D-PAGE gels were generated. Proteins were separated by
isoelectric focusing on a pH gradient of 3-10 in the first dimension. Proteins were then
separated by molecular weight on a 10% acrylamide gel in the second dimension.
Proteins were visualized with silver stain and identical protein spots were cored from the
gel and combined in a single tube. The letter labeling system corresponds to the labels in
Figure 2.1.
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Figure A3.2: Additional parallel gels of late-log protein preparations of P.
agglomerans secreted proteins. In order to increase the amount of protein per sample
(spot) sent for identification, parallel 2D-PAGE gels were generated. Proteins were
separated by isoelectric focusing on a pH gradient of 3-10 in the first dimension. Proteins
were then separated by molecular weight on a 10% acrylamide gel in the second
dimension. Proteins were visualized with silver stain and identical protein spots were
cored from the gel and combined in a single tube. The letter labeling system corresponds
to the labels in Figure 2.1.
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